{"gene":"CCR3","run_date":"2026-04-28T17:28:52","timeline":{"discoveries":[{"year":1996,"finding":"CCR3, when co-expressed with CD4 on otherwise non-permissive cells, functions as a co-receptor (fusion cofactor) for a restricted subset of primary HIV-1 isolates; binding of the CCR3 ligand eotaxin blocks this infection, and utilization depends on the V3 region of HIV-1 gp120.","method":"Cell-based infection/fusion assay with CCR3 transfectants, co-expression of CD4 and CCR3, chemokine inhibition experiments","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1-2 — two independent Cell papers using cell-line reconstitution and functional fusion/infection assays; replicated","pmids":["8674119","8674120"],"is_preprint":false},{"year":1997,"finding":"CCR3 is selectively expressed on human Th2 cells; eotaxin stimulation through CCR3 induces intracellular calcium increases and chemotaxis of CCR3+ T cells, and these cells produce IL-4 and IL-5.","method":"Anti-CCR3 antibody-based cell isolation, intracellular Ca2+ flux assay, chemotaxis assay, cytokine production measurement","journal":"Science","confidence":"High","confidence_rationale":"Tier 2 — reciprocal functional validation with blocking antibody and Ca2+ flux, replicated in multiple labs","pmids":["9302298","9480044"],"is_preprint":false},{"year":1997,"finding":"CCR3 mediates eosinophil responses (chemotaxis and calcium flux) to multiple CC chemokines including eotaxin, RANTES, MCP-2, MCP-3, and MCP-4; a selective antagonistic monoclonal antibody (7B11) blocks >95% of these responses.","method":"Radiolabeled chemokine binding competition assay, calcium flux assay, chemotaxis assay with antagonistic mAb 7B11","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal assays, specific mAb antagonism confirming receptor mediating all responses","pmids":["9005985"],"is_preprint":false},{"year":1997,"finding":"Alanine scanning mutagenesis of RANTES identified distinct but overlapping binding epitopes for CCR3 (F12 in N-loop), CCR1 (R17), and CCR5 (F12, I15, P2); residues P2 and Y3 near the RANTES N-terminus are required for CCR3 signal transduction, defining a two-site model of chemokine-receptor interaction.","method":"Alanine scanning mutagenesis of RANTES, receptor binding assays, calcium mobilization assays","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 — systematic mutagenesis with binding and functional readouts","pmids":["9289016"],"is_preprint":false},{"year":1997,"finding":"CCR3 function is highly sensitive to extracellular pH and NaCl concentration; small physiological variations dramatically alter eotaxin binding, CCR3-mediated Ca2+ mobilization, and eosinophil migration, suggesting the tissue microenvironment modulates CCR3 affinity.","method":"Radiolabeled ligand binding assay, intracellular Ca2+ mobilization assay, eosinophil migration assay under varied pH and salt conditions","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 — multiple orthogonal in vitro assays in single study","pmids":["9353270"],"is_preprint":false},{"year":1998,"finding":"CCR3 (but not CCR5) is the essential co-receptor for microglia HIV-1 infection among CCR3/CCR5-expressing cells; antibodies to CCR5 but not CCR3 prevented monocyte infection, establishing differential receptor usage in mononuclear phagocyte subsets.","method":"Antibody blockade of CCR3 and CCR5, infection of purified monocyte and microglia populations with macrophage-tropic HIV-1 strains","journal":"Journal of virology","confidence":"Medium","confidence_rationale":"Tier 2 — direct antibody blockade in primary cell infection assays","pmids":["9525662"],"is_preprint":false},{"year":1998,"finding":"IFN-γ upregulates CCR3 (along with CCR1 and CCR5) surface expression and mRNA in monocytoid U937 cells, resulting in enhanced Ca2+ mobilization, chemotaxis, and increased HIV-1 entry.","method":"Flow cytometry, mRNA expression, Ca2+ mobilization, cell migration assays, HIV-1 entry assay in IFN-γ-treated U937 cells","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 — multiple orthogonal methods in a single study","pmids":["9616137"],"is_preprint":false},{"year":1998,"finding":"RANTES enhances HIV-1-specific CTL killing via CCR3; the effect is blocked by a CCR3-specific antibody and by pertussis toxin, indicating G protein-coupled CCR3 signaling mediates this cytotoxic enhancement. MCP-3, MCP-4, and eotaxin also enhance lysis through CCR3, while CCR1, CCR2, CCR5, and CXCR4 ligands are inactive.","method":"CTL killing assay with specific antibody blockade, pertussis toxin treatment, chemokine panel testing","journal":"The Journal of experimental medicine","confidence":"Medium","confidence_rationale":"Tier 2 — functional blockade with specific antibody and G-protein inhibitor","pmids":["9687538"],"is_preprint":false},{"year":1999,"finding":"Eotaxin stimulation through CCR3 induces tyrosine phosphorylation of multiple cellular proteins in eosinophils, recruits Src family kinases Hck and c-Fgr to CCR3 after receptor internalization, and causes actin reorganization; herbimycin A (tyrosine kinase inhibitor) blocks both phosphorylation and chemotaxis.","method":"Co-immunoprecipitation, immunofluorescence microscopy, tyrosine kinase inhibitor treatment, chemotaxis assay","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 — co-IP showing direct association of Hck/c-Fgr with CCR3, functional inhibitor validation","pmids":["10527858"],"is_preprint":false},{"year":1999,"finding":"CCR3 mediates eosinophil shape change in response to eotaxin, eotaxin-2, MCP-4, and RANTES; MIP-1α induces eosinophil responses through a non-CCR3 pathway (likely CCR1); pre-incubation without extracellular Ca2+ upregulates non-CCR3 signaling pathways.","method":"Gated autofluorescence/forward scatter assay for leukocyte shape change, antibody blocking of CCR3","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 — pathway discrimination using specific antibody blocking in primary cells","pmids":["10072545"],"is_preprint":false},{"year":2000,"finding":"CCR3 chemokine-induced eosinophil degranulation (release of eosinophil-derived neurotoxin) is mediated exclusively through CCR3; although non-CCR3 ligands (e.g., MCP-1) induce Ca2+ flux, only CCR3 ligands (MCP-3, MCP-4, RANTES, eotaxin) induce degranulation; IL-5 priming enhances CCR3-dependent but not non-CCR3 degranulation.","method":"Ca2+ flux assay, RIA for eosinophil-derived neurotoxin, CCR3-specific antibody blocking, IL-5 priming","journal":"The Journal of allergy and clinical immunology","confidence":"Medium","confidence_rationale":"Tier 2 — antibody blockade with multiple chemokines, specific functional readout","pmids":["10984371"],"is_preprint":false},{"year":2000,"finding":"The N-terminal peptide of CCR3 (residues 1–35 and 8–23) binds eotaxin with low affinity (Kd ~80–136 µM); NMR spectroscopy identified the N-loop/β2-β3 hairpin groove of eotaxin as the binding surface; the central DDYY region of the CCR3 N-terminus is involved in the interaction.","method":"Synthetic peptide binding assay, 1H-15N NMR spectroscopy, 15N-filtered TOCSY","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — NMR structural characterization with peptide binding experiments","pmids":["10859315"],"is_preprint":false},{"year":2000,"finding":"CCR3 signaling in eosinophilic AML14.3D10 cells does not inhibit adenylate cyclase (unlike most GPCRs), uses pertussis toxin-sensitive Ca2+ transients inhibited by PMA but not forskolin, and eotaxin stimulation causes rapid and prolonged receptor internalization without degradation.","method":"cAMP assay, Ca2+ flux assay, pertussis toxin and PMA treatment, receptor internalization/degradation assays, CCR3 promoter-luciferase reporter","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 — multiple signaling pathway assays in eosinophilic cell line","pmids":["10623856"],"is_preprint":false},{"year":2000,"finding":"CCL11 (eotaxin) binds with high affinity to CXCR3, which can act as a decoy receptor sequestering CCL11; CXCR3 ligands (CXCL9, CXCL10, CXCL11) inhibit CCR3-mediated eosinophil responses by acting as CCR3 antagonists; CCR3-CCR1 chimeric receptor analysis revealed that CCL11 and CXCL11 share overlapping binding sites in the CCR3 extracellular loops.","method":"Binding assays, chemotaxis assay, Ca2+ flux, CCR3-CCR1 chimeric receptor construction and analysis","journal":"European journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 — chimeric receptor mapping combined with functional assays","pmids":["12884299"],"is_preprint":false},{"year":2001,"finding":"CCR3 is expressed on human airway epithelial cells and is functional: eotaxin stimulation induces intracellular Ca2+ flux and tyrosine phosphorylation, blocked by anti-CCR3 mAb (7B11) or pertussis toxin; 125I-eotaxin binding confirmed expected ligand specificity.","method":"Northern blot, Western blot, flow cytometry, Ca2+ flux assay, tyrosine phosphorylation assay, 125I-eotaxin binding assay, mAb blockade, pertussis toxin treatment","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal methods confirming functional receptor expression in a non-leukocyte cell type","pmids":["11160184"],"is_preprint":false},{"year":2001,"finding":"CCR3 expressed on human mast cells mediates chemotaxis in response to eotaxin and RANTES; pre-incubation with anti-CCR3 antibody abrogates eotaxin-induced mast cell migration, but eotaxin does not induce histamine release from lung mast cells.","method":"Immunohistochemistry, flow cytometry, chemotaxis assay with anti-CCR3 antibody blockade, histamine release assay","journal":"International archives of allergy and immunology","confidence":"Medium","confidence_rationale":"Tier 2 — antibody blockade in primary cell chemotaxis and degranulation assays","pmids":["11306952"],"is_preprint":false},{"year":2001,"finding":"CCL11 (eotaxin) promotes angiogenesis via CCR3 expressed on human microvascular endothelial cells; CCL11-induced endothelial chemotaxis was inhibited by antibodies to CCL11 or CCR3; in vivo angiogenesis (chick CAM and Matrigel assays) was confirmed, and rat aortic sprouting assay showed the response is direct (not eosinophil-mediated).","method":"Endothelial chemotaxis assay with antibody blockade, chick chorioallantoic membrane assay, Matrigel plug assay, rat aortic sprouting assay","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 1-2 — multiple in vivo and in vitro angiogenesis assays with antibody blockade, direct mechanism demonstrated","pmids":["11390513"],"is_preprint":false},{"year":2001,"finding":"The IKK-2/IκBα/NF-κB pathway regulates CCR3 expression in fibroblasts: transdominant IκBα mutant blocks TNF-α-induced CCR3 expression, and constitutively active IKK-2 drives CCR3 expression without TNF-α; IκBα-deficient mice show elevated CCR3 in skin associated with dermatitis.","method":"Stable transfection of IκBα and IKK-2 mutants, luciferase reporter assay, immunohistochemistry in knockout mice, RT-PCR","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 — genetic and biochemical pathway dissection with both gain- and loss-of-function mutants in cells and in vivo","pmids":["11694538"],"is_preprint":false},{"year":2002,"finding":"Alanine scanning mutagenesis of CCR3's three intracellular loops revealed all three are required for G protein coupling and chemotactic function; in ICL2, the DRY motif residues D130 and R131 require acidic/basic character for function; Y132 is critical for surface expression and chemotaxis.","method":"Site-directed alanine triplet and point mutagenesis, flow cytometry for surface expression, chemotaxis assay","journal":"European journal of immunology","confidence":"High","confidence_rationale":"Tier 1 — systematic mutagenesis (15 triplet + 7 point mutants) with defined structural-functional readouts","pmids":["11920572"],"is_preprint":false},{"year":2002,"finding":"CCR3 is essential for skin and lung eosinophilia and airway hyperresponsiveness in a murine model of epicutaneous OVA sensitization; CCR3-/- mice lack skin and lung eosinophils and fail to develop AHR despite normal IgE, Th2 cytokines (IL-4/IL-5), and mast cell numbers.","method":"CCR3 knockout mouse model, epicutaneous OVA sensitization, histology, BAL cell counts, AHR measurement, cytokine quantification","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 — CCR3 KO with rigorous controls and multiple phenotypic readouts","pmids":["11877470"],"is_preprint":false},{"year":2002,"finding":"IL-16 activates eosinophils via CD4 receptor to release preformed RANTES, which then autocrinally signals through CCR3 to stimulate LTC4 production and preferential IL-4 (not IL-12) release; CCR3 inhibitors (Met-RANTES, anti-CCR3 mAb) and neutralizing anti-eotaxin/anti-RANTES antibodies block these effects.","method":"LTC4 and cytokine RIA, antibody blockade (anti-CD4, anti-CCR3, anti-RANTES, anti-eotaxin), pertussis toxin, Met-RANTES antagonism, brefeldin A treatment","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — multiple blocking reagents and mechanistic dissection of autocrine CCR3 signaling pathway","pmids":["11971026"],"is_preprint":false},{"year":2003,"finding":"Eotaxin induces Ca2+ mobilization and chemotaxis in CD34+ cord blood progenitor cells via CCR3, and directly drives eosinophil differentiation from CD34+ progenitors; Th2 cytokines (IL-4, IL-13) upregulate CCR3 on progenitors while IL-12/IFN-γ decrease it; this differentiation is IL-3-, IL-5-, and GM-CSF-independent.","method":"In situ RT-PCR, immunostaining, flow cytometry, Ca2+ mobilization assay, in vitro differentiation assay with neutralizing antibodies","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 — functional Ca2+ and differentiation assays with neutralizing antibody controls","pmids":["12496441"],"is_preprint":false},{"year":2004,"finding":"CCL11 (eotaxin) induces vascular smooth muscle cell (SMC) migration via CCR3; CCR3 mRNA and protein are present in mouse aortic SMCs; migration is inhibited by anti-CCR3 but not anti-CCR2 antibody; CCR3 and CCL11 are upregulated in SMCs after arterial injury.","method":"RT-PCR, Western blot, flow cytometry, Boyden chamber chemotaxis, scrape-wound assay with specific antibody blockade, in vivo arterial injury model","journal":"Arteriosclerosis, thrombosis, and vascular biology","confidence":"High","confidence_rationale":"Tier 1-2 — multiple methods including receptor-specific antibody blockade in both in vitro and in vivo contexts","pmids":["15130922"],"is_preprint":false},{"year":2004,"finding":"CCR3 in bronchial epithelial cells transactivates the epidermal growth factor receptor (EGFR) upon eotaxin stimulation; EGFR tyrosine phosphorylation is dose-dependent; EGFR inhibitor AG1478 blocks CCR3-induced MAP kinase phosphorylation and IL-8 production.","method":"Western blot for EGFR phosphorylation, EGFR inhibitor (AG1478) treatment, ELISA for IL-8 in bronchial epithelial cells","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 — pharmacological inhibitor defining EGFR as downstream effector of CCR3","pmids":["15219825"],"is_preprint":false},{"year":2005,"finding":"Eotaxin-2 has a dominant role in airway (luminal) eosinophilia in allergen-induced asthma; combined deletion of eotaxin-1 and eotaxin-2 (DKO) and CCR3 deletion both markedly reduce tissue eosinophilia, abolish organized peribronchial/perivascular eosinophil accumulation, and eotaxin-2 is expressed by macrophages in BAL fluid.","method":"Genetic deletion (eotaxin-1 KO, eotaxin-2 KO, eotaxin-1/2 DKO, CCR3 KO), OVA-induced asthma model, BAL and tissue eosinophil counts","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — epistasis analysis with multiple KO combinations showing CCR3 is downstream of eotaxins","pmids":["16210640"],"is_preprint":false},{"year":2005,"finding":"CXCL9 (Mig) inhibits eosinophil chemoattraction and F-actin formation through a CCR3-dependent mechanism by blocking eotaxin-induced Rac GTPase activation; Rac2-deficient eosinophils show impaired transmigration and actin polymerization, and CXCL9 cannot inhibit responses in CCR3-deficient eosinophils, establishing CCR3 as the mediator of this inhibitory signal.","method":"CCR3 and Rac2 gene-targeted eosinophils, F-actin formation assay, Rac GTPase activation assay, transmigration assay","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1-2 — genetic deletion of CCR3 and Rac2 combined with biochemical pathway analysis","pmids":["15802529"],"is_preprint":false},{"year":2006,"finding":"Oligodendrocyte precursor cells (OPCs) express functional CCR3; CCL11 stimulation induces intracellular Ca2+ rise and concentration-specific effects: increased proliferation, inhibition of migration, and augmentation of differentiation in primary OPCs.","method":"RT-PCR, immunofluorescence, Ca2+ mobilization assay, proliferation, migration, and differentiation assays in primary rat OPCs","journal":"Journal of neuroimmunology","confidence":"Medium","confidence_rationale":"Tier 2 — multiple functional readouts in primary cells","pmids":["16828880"],"is_preprint":false},{"year":2006,"finding":"CCR3 on airway epithelial cells mediates wound repair, cell proliferation, and chemotaxis in response to CCL24 (eotaxin-2), with comparable potency to EGF; CCL11 induces upregulation of profibrogenic genes (FGF-1, FGF-5) and CC/CXC chemokines; a selective CCR3 antagonist inhibits these responses.","method":"In vitro wound model, fluorometric proliferation and chemotaxis assays, pathway-specific gene arrays, CCR3 antagonist blockade, immunostaining of bronchial biopsies","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal functional assays with pharmacological inhibitor validation","pmids":["16920975"],"is_preprint":false},{"year":2009,"finding":"CCR3 is specifically expressed on choroidal neovascular endothelial cells in AMD patients; genetic or pharmacological targeting of CCR3 or its eotaxin ligands inhibits injury-induced CNV in mice; CNV suppression by CCR3 blockade is due to direct inhibition of endothelial cell proliferation, is uncoupled from inflammation, and occurs in mice lacking eosinophils or mast cells.","method":"Immunohistochemistry, CCR3 genetic knockout/pharmacological blockade, laser-induced CNV mouse model, in vitro endothelial cell proliferation assay in mice lacking eosinophils/mast cells, quantum dot in vivo imaging","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1-2 — multiple genetic and pharmacological approaches with rigorous controls separating CCR3 function from inflammation","pmids":["19525930"],"is_preprint":false},{"year":2011,"finding":"Activated CCR3 promotes choroidal endothelial cell (CEC) migration and Rac1 activation; ligand-activated CCR3 causes transphosphorylation and co-immunoprecipitation of VEGFR2 with CCR3, demonstrating cross-talk between CCR3 and VEGF signaling pathways; CCR3 inhibitor prevents VEGF-induced CEC migration and Rac1 activation.","method":"CCL11-stimulated CEC migration assay, Rac1 activity assay, phospho-Akt and phospho-VEGFR2 Western blot, co-immunoprecipitation of CCR3 and VEGFR2, CCR3 inhibitor treatment","journal":"Investigative ophthalmology & visual science","confidence":"High","confidence_rationale":"Tier 1-2 — co-IP demonstrating physical interaction plus multiple downstream signaling readouts","pmids":["21917937"],"is_preprint":false},{"year":2011,"finding":"CCL11 promotes survival of anaplastic large cell lymphoma cells via CCR3-mediated ERK1/2 phosphorylation, inducing anti-apoptotic proteins Bcl-xL and survivin; ERK phosphorylation inhibition completely blocks CCL11-mediated cell survival; autocrine CCL11-CCR3 signaling drives tumor growth in vivo.","method":"Cell viability assay, Western blot for ERK1/2 phosphorylation and Bcl-xL/survivin, ERK inhibitor treatment, in vivo tumor growth in CCR3+ cell lines","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 — ERK pathway inhibitor dissection with in vivo validation","pmids":["21406396"],"is_preprint":false},{"year":2013,"finding":"CCR3 on human dermal fibroblasts mediates intracellular Ca2+ mobilization, enhanced fibroblast migration, and wound repair capacity in response to CCL26 (eotaxin-3); CCL26 is specifically upregulated in atopic (vs. psoriatic) skin by IL-4 and IL-13, implicating CCR3-mediated CCL26-fibroblast signaling in atopic skin tissue remodeling.","method":"Flow cytometry, immunofluorescence, Ca2+ mobilization assay, cell proliferation, migration, and repair capacity assays in dermal fibroblasts","journal":"Journal of dermatological science","confidence":"Medium","confidence_rationale":"Tier 2 — multiple functional assays in primary cells with cytokine regulation","pmids":["23702389"],"is_preprint":false},{"year":2013,"finding":"CCR3-mediated secretion of eosinophil-associated RNases (EARs) requires activation of PI3K, ERK, and p38 MAPK, and is Gαi-dependent; β1 and β2 integrins are essential for EAR secretion, and spreading is obligatory for secretion in both mouse and human eosinophils.","method":"RNase activity assay, specific signaling inhibitors for PI3K/ERK/p38 MAPK, integrin blocking antibodies, pertussis toxin, adhesion microscopy in primary mouse and human eosinophils","journal":"Allergy","confidence":"Medium","confidence_rationale":"Tier 2 — pathway dissection with multiple specific inhibitors in primary cells","pmids":["23742707"],"is_preprint":false},{"year":2014,"finding":"Sulfotyrosine residues in the N-terminal region (residues 8–23) of CCR3 dramatically enhance binding to CCL11/eotaxin-1; crystal structure of CCL11 bound to sulfo-CCR3(8–23) peptide reveals sulfotyrosine residues form hydrophobic, salt bridge, and cation-π interactions with conserved CC chemokine residues; intact CCR3 is sulfated in cells and sulfation enhances receptor activity.","method":"X-ray crystallography (NMR structure of peptide-chemokine complex), sulfopeptide binding assays, receptor activity assays, mass spectrometry for sulfation","journal":"Structure","confidence":"High","confidence_rationale":"Tier 1 — crystal structure with functional validation of sulfotyrosine-mediated receptor-ligand recognition","pmids":["25450766"],"is_preprint":false},{"year":2016,"finding":"CCL11 (CCR3 ligand) activates CDK5 and GSK-3β via CCR3, leading to tau hyperphosphorylation, Aβ production, and dendritic spine loss in hippocampal neurons; CCR3 deletion in APP/PS1 mice significantly reduces CDK5/GSK-3β phosphorylation, tau hyperphosphorylation, Aβ deposition, and synaptic loss; all CCL11 effects are blocked by CCR3 antagonist GW766994.","method":"Primary hippocampal neuronal culture, Western blot for CDK5/GSK-3β/tau phosphorylation, Aβ ELISA, dendritic spine analysis, CCR3 KO in AD transgenic mice, CCR3 antagonist treatment","journal":"Molecular neurobiology","confidence":"High","confidence_rationale":"Tier 1-2 — genetic (KO) and pharmacological (specific antagonist) approaches with multiple downstream mechanistic readouts","pmids":["27878757"],"is_preprint":false},{"year":2016,"finding":"CCL7-CCR3 interaction in colon cancer cells promotes cellular proliferation, invasion, and migration via ERK and JNK signaling pathways; CCL7-overexpressing cells form faster-growing tumors and develop liver/lung metastases in orthotopic mouse models.","method":"CCL7-overexpressing HCT116/HT29 cell lines, in vitro proliferation/invasion/migration assays, ERK/JNK Western blots, ectopic and orthotopic mouse tumor models","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2 — in vitro signaling plus in vivo tumor models","pmids":["27167205"],"is_preprint":false},{"year":2018,"finding":"A biased CCR3 peptide nanoparticle antagonist (R321) inhibits only the early phase of ERK1/2 activation (not the late β-arrestin-associated phase), promotes CCR3 internalization and degradation, and effectively blocks eosinophil recruitment and airway hyperresponsiveness in a mouse asthma model.","method":"Dynamic light scattering, NMR peptide binding, flow cytometry, confocal microscopy, Western blot for ERK1/2 phases, in vivo triple-allergen mouse asthma model","journal":"The Journal of allergy and clinical immunology","confidence":"Medium","confidence_rationale":"Tier 2 — biased signaling mechanism demonstrated with multiple methods in vitro and in vivo","pmids":["29778505"],"is_preprint":false},{"year":2021,"finding":"Cholesterol acts as a dose-dependent positive allosteric modulator of CCR3: increasing cholesterol concentration enhances CCR3 affinity for CCL11 in both SMALPs and proteoliposomes, and this heightened receptor activation directly increases GTPase activity of the bound Gαi3 subunit.","method":"In vitro CCR3 reconstitution in SMALPs and proteoliposomes, ligand binding assay, GTPase activity assay with purified E. coli-expressed CCR3","journal":"Frontiers in molecular biosciences","confidence":"High","confidence_rationale":"Tier 1 — reconstituted in vitro with purified receptor, direct biochemical measurement of allosteric modulation of both binding and G protein activity","pmids":["34490352"],"is_preprint":false},{"year":2022,"finding":"Cryo-EM structure of CCR3 in the apo state and functional analysis show that interactions around intracellular loop 2 (ICL2) are conserved and play a more critical role in G-protein activation than ICL3 interactions; extensive hydrophobic and polar interactions between CCR3 and Gα contribute to constitutive receptor activity.","method":"Cryo-electron microscopy structure determination, complementary functional experiments (G protein coupling assays)","journal":"Cell discovery","confidence":"High","confidence_rationale":"Tier 1 — cryo-EM structure with functional validation","pmids":["35570218"],"is_preprint":false},{"year":2022,"finding":"The CCL24/CCR3 axis promotes cardiac fibroblast activation and M2 macrophage polarization; CCR3 is expressed on cardiac macrophages and fibroblasts; CCL24 promotes primary cardiac fibroblast activation through its G protein-coupled receptor function; CCL24 antibody treatment prevents Ang II-induced cardiac hypertrophy and fibrosis.","method":"Immunofluorescence co-localization, RNA-seq, CyTOF single-cell analysis, in vitro fibroblast activation assay, in vivo Ang II heart failure model with CCL24 antibody","journal":"Cell biology and toxicology","confidence":"Medium","confidence_rationale":"Tier 2 — multiple orthogonal methods linking CCR3 GPCR function to fibroblast activation","pmids":["36131165"],"is_preprint":false}],"current_model":"CCR3 is a Gαi-coupled, seven-transmembrane CC chemokine receptor that is expressed on eosinophils, basophils, mast cells, Th2 lymphocytes, airway epithelial cells, endothelial cells, smooth muscle cells, and certain neurons/oligodendrocytes; upon binding to eotaxins (CCL11/24/26), RANTES, MCP-3, MCP-4, or CCL7/CCL28, it triggers pertussis toxin-sensitive Ca2+ flux, Src-family kinase (Hck/c-Fgr) recruitment, PI3K-ERK-p38 MAPK activation, Rac2-dependent actin reorganization, receptor internalization, and—in specialized contexts—EGFR transactivation and VEGFR2 cross-talk, thereby driving eosinophil chemotaxis, degranulation, and EAR secretion, Th2 cell recruitment, endothelial angiogenesis, smooth muscle cell migration, fibroblast wound repair, and choroidal neovascularization; its activity is regulated by sulfotyrosine-mediated high-affinity ligand binding at the receptor N-terminus, cholesterol allosteric modulation of Gαi coupling, NF-κB (IKK-2/IκBα)-dependent transcription, and antagonism by CXCR3 ligands acting as CCR3 receptor antagonists."},"narrative":{"teleology":[{"year":1996,"claim":"Identification of CCR3 as a functional chemokine receptor that also serves as an HIV-1 co-receptor established it as a seven-transmembrane signaling molecule with dual roles in chemokine biology and viral entry.","evidence":"Cell-based infection/fusion assays with CCR3 transfectants co-expressing CD4, ligand competition","pmids":["8674119","8674120"],"confidence":"High","gaps":["Downstream signaling events upon HIV-1 gp120 engagement of CCR3 undefined","Whether CCR3 serves as HIV-1 co-receptor in vivo undetermined"]},{"year":1997,"claim":"Demonstration that CCR3 is the dominant receptor mediating eosinophil and Th2 cell chemotaxis to multiple CC chemokines (eotaxin, RANTES, MCP-2/3/4) established its central role in type 2 immune cell trafficking.","evidence":"Antagonistic mAb 7B11, Ca²⁺ flux, radiolabeled binding competition, Th2 isolation and cytokine profiling","pmids":["9005985","9302298","9480044"],"confidence":"High","gaps":["Intracellular signaling cascade downstream of CCR3 not yet mapped","Relative contribution of each ligand in vivo unknown"]},{"year":1997,"claim":"Alanine scanning of RANTES and characterization of CCR3 sensitivity to pH/NaCl defined a two-site chemokine–receptor interaction model and revealed that microenvironmental conditions tune CCR3 ligand affinity.","evidence":"Systematic RANTES mutagenesis with binding/Ca²⁺ assays; ligand binding under varied ionic/pH conditions","pmids":["9289016","9353270"],"confidence":"High","gaps":["Structural basis for pH sensitivity not determined","In vivo relevance of microenvironmental modulation unproven"]},{"year":1999,"claim":"Discovery that eotaxin-activated CCR3 recruits Src-family kinases Hck and c-Fgr and drives actin reorganization linked receptor engagement to a defined tyrosine kinase signaling axis required for eosinophil chemotaxis.","evidence":"Co-immunoprecipitation of Hck/c-Fgr with CCR3 post-internalization, herbimycin A inhibition, immunofluorescence","pmids":["10527858"],"confidence":"Medium","gaps":["No reciprocal pull-down or direct binding assay for Hck/c-Fgr–CCR3 interaction","Kinase substrates downstream of Hck/c-Fgr not identified","Role of receptor internalization in kinase recruitment unclear"]},{"year":2000,"claim":"Functional dissection revealed that CCR3 exclusively mediates eosinophil degranulation (EDN release) even though non-CCR3 pathways can trigger Ca²⁺ flux, and NMR mapping identified the CCR3 N-terminal DDYY region and eotaxin N-loop groove as the initial binding interface.","evidence":"CCR3-specific antibody blocking of degranulation vs. Ca²⁺; ¹H-¹⁵N NMR of eotaxin–CCR3 peptide complex","pmids":["10984371","10859315"],"confidence":"High","gaps":["Full-length receptor–ligand complex structure not solved","Structural basis for coupling between binding and degranulation signaling not established"]},{"year":2001,"claim":"Extending CCR3 function beyond leukocytes, studies showed it mediates angiogenesis in endothelial cells, signals in airway epithelium, directs mast cell chemotaxis, and is transcriptionally regulated by the IKK-2/IκBα/NF-κB pathway.","evidence":"Chick CAM/Matrigel/aortic ring angiogenesis assays, epithelial Ca²⁺ flux and tyrosine phosphorylation, mast cell migration with anti-CCR3, gain/loss-of-function IKK-2/IκBα mutants and IκBα-KO mice","pmids":["11390513","11160184","11306952","11694538"],"confidence":"High","gaps":["NF-κB binding sites on CCR3 promoter not mapped","Relative importance of CCR3 vs. VEGFR signaling in angiogenesis unclear"]},{"year":2002,"claim":"CCR3 knockout mice lack eosinophilic inflammation and airway hyperresponsiveness in allergic models, and systematic intracellular-loop mutagenesis defined the DRY motif and all three ICLs as essential for G protein coupling, establishing CCR3 as non-redundant for allergic eosinophilia in vivo.","evidence":"CCR3-KO epicutaneous OVA model; alanine-scanning mutagenesis of 15 ICL triplets with chemotaxis readout","pmids":["11877470","11920572"],"confidence":"High","gaps":["Other compensatory receptors in chronic settings not evaluated","Exact Gα subunit preference at ICL interfaces not biochemically defined"]},{"year":2005,"claim":"Genetic epistasis showed eotaxin-1/eotaxin-2 double knockouts phenocopy CCR3 deletion for airway eosinophilia, and CXCL9 was found to inhibit CCR3-mediated Rac2 activation directly through the receptor, establishing a natural antagonist mechanism.","evidence":"Multiple KO combinations in OVA asthma model; Rac2-KO and CCR3-KO eosinophil F-actin and transmigration assays","pmids":["16210640","15802529"],"confidence":"High","gaps":["Structural basis for CXCR3-ligand antagonism at CCR3 not resolved","Role of Rac1 vs. Rac2 in different CCR3-expressing cell types not distinguished"]},{"year":2009,"claim":"CCR3 was identified as specifically expressed on choroidal neovascular endothelium in AMD patients, and its blockade inhibited CNV independently of eosinophils/mast cells, establishing a direct pro-angiogenic function.","evidence":"Immunohistochemistry of human AMD tissue, CCR3-KO and pharmacological blockade in laser-induced CNV, endothelial proliferation in eosinophil/mast-cell-deficient mice","pmids":["19525930"],"confidence":"High","gaps":["Which eotaxin drives CNV in human AMD not determined","Clinical efficacy of CCR3 blockade in AMD not validated"]},{"year":2011,"claim":"CCR3 transphosphorylates and physically associates with VEGFR2 in choroidal endothelial cells, and drives ALCL survival through ERK–Bcl-xL/survivin, revealing receptor cross-talk and pro-survival signaling as additional mechanistic outputs.","evidence":"Co-IP of CCR3–VEGFR2, phospho-VEGFR2/Akt/Rac1 Western blots; ERK inhibitor blockade of ALCL cell survival and in vivo tumor growth","pmids":["21917937","21406396"],"confidence":"High","gaps":["Whether CCR3–VEGFR2 complex forms in other vascular beds unknown","Direct kinase responsible for VEGFR2 transphosphorylation not identified"]},{"year":2013,"claim":"CCR3-mediated EAR secretion was mapped to a Gαi→PI3K→ERK/p38 MAPK cascade requiring integrin-dependent spreading, and CCL26–CCR3 was shown to drive dermal fibroblast wound repair, expanding the receptor's downstream signaling map and tissue-remodeling roles.","evidence":"Specific signaling inhibitors and integrin-blocking antibodies in primary eosinophils; Ca²⁺/migration/wound-repair assays in dermal fibroblasts","pmids":["23742707","23702389"],"confidence":"Medium","gaps":["PI3K isoform specificity not determined","Whether integrin requirement reflects co-signaling or physical constraint not resolved"]},{"year":2014,"claim":"Crystal structure of the sulfo-CCR3 N-terminal peptide bound to CCL11 revealed that sulfotyrosine residues form specific salt-bridge, hydrophobic, and cation-π contacts with conserved chemokine residues, explaining high-affinity ligand recognition.","evidence":"X-ray crystallography of sulfo-CCR3(8–23)–CCL11 complex, mass spectrometry confirming sulfation, receptor activity assays","pmids":["25450766"],"confidence":"High","gaps":["Full-length CCR3–CCL11 complex structure not solved","Contribution of individual sulfotyrosines to in vivo signaling not determined"]},{"year":2016,"claim":"CCR3 activation by CCL11 in neurons triggers CDK5/GSK-3β-mediated tau hyperphosphorylation and Aβ production; CCR3 deletion in APP/PS1 mice reduces Alzheimer-related pathology, linking CCR3 to neurodegeneration.","evidence":"CCR3-KO crossed with APP/PS1 transgenic mice, CCR3 antagonist GW766994, Western blots for tau/CDK5/GSK-3β phosphorylation, Aβ ELISA, dendritic spine analysis","pmids":["27878757"],"confidence":"High","gaps":["Source of CCL11 in the AD brain not identified","Whether CCR3 blockade is therapeutic after disease onset unknown"]},{"year":2018,"claim":"A biased CCR3 peptide nanoparticle antagonist (R321) selectively inhibits early G protein-dependent ERK activation while sparing β-arrestin-mediated signaling, promoting receptor degradation and blocking eosinophil recruitment in vivo, demonstrating pharmacologically exploitable signaling bias.","evidence":"NMR peptide binding, ERK phase dissection by Western blot, confocal internalization/degradation, triple-allergen mouse asthma model","pmids":["29778505"],"confidence":"Medium","gaps":["β-arrestin pathway contributions to CCR3 biology in vivo not resolved","Single study; biased agonism not independently confirmed"]},{"year":2021,"claim":"Reconstitution of purified CCR3 in defined lipid environments demonstrated that cholesterol is a dose-dependent positive allosteric modulator, directly enhancing both CCL11 binding affinity and Gαi3 GTPase activity.","evidence":"Purified E. coli-expressed CCR3 in SMALPs and proteoliposomes with titrated cholesterol, GTPase activity assay","pmids":["34490352"],"confidence":"High","gaps":["Cholesterol binding site on CCR3 not structurally identified","Physiological range of membrane cholesterol variation in eosinophils not characterized"]},{"year":2022,"claim":"Cryo-EM structure of apo CCR3 revealed that ICL2 interactions with Gα are more critical than ICL3 for G protein activation and provided structural basis for constitutive receptor activity, completing the structural picture of CCR3–G protein coupling.","evidence":"Cryo-EM structure determination with complementary G protein coupling functional assays","pmids":["35570218"],"confidence":"High","gaps":["Ligand-bound active-state cryo-EM structure not yet solved","Structural basis for biased signaling (G protein vs. β-arrestin) not resolved"]},{"year":null,"claim":"A complete structural understanding of CCR3 activation—including a full-length CCR3–chemokine–Gi ternary complex structure, the molecular basis for β-arrestin-biased signaling, and the cholesterol binding site—remains to be determined.","evidence":"","pmids":[],"confidence":"High","gaps":["No ternary complex structure of full-length CCR3–ligand–Gi","Molecular basis of β-arrestin-biased vs. G protein-biased signaling unknown","In vivo therapeutic efficacy of CCR3-targeted agents in AMD and neurodegeneration not established"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[1,2,9,12,14,38]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[25,36,37]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[1,2,14,15,16,22,28,38]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[1,2,7,10,19,20,24,25,32,36]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[8,12,18,23,25,29,30,32,34,37,38]}],"complexes":[],"partners":["CCL11","CCL24","CCL26","CCL5","VEGFR2","HCK","FGR","RAC2"],"other_free_text":[]},"mechanistic_narrative":"CCR3 is a Gαi-coupled seven-transmembrane CC chemokine receptor that orchestrates eosinophil recruitment, degranulation, and effector function in allergic inflammation, while also mediating angiogenesis, tissue remodeling, and neurodegeneration in non-hematopoietic contexts. The receptor binds eotaxins (CCL11/CCL24/CCL26), RANTES, MCP-3, MCP-4, and CCL7 via an N-terminal sulfotyrosine-dependent recognition site, triggering pertussis toxin-sensitive Ca²⁺ flux, Src-family kinase (Hck/c-Fgr) recruitment, PI3K–ERK–p38 MAPK activation, and Rac2-dependent actin reorganization that collectively drive chemotaxis, shape change, and eosinophil-associated RNase secretion [PMID:9005985, PMID:10527858, PMID:23742707, PMID:25450766]. Beyond leukocytes, CCR3 functions on airway epithelial cells, endothelial cells, smooth muscle cells, fibroblasts, and neurons, where it transactivates EGFR, cross-talks with VEGFR2, and activates CDK5/GSK-3β to promote wound repair, choroidal neovascularization, and tau hyperphosphorylation respectively [PMID:15219825, PMID:21917937, PMID:27878757, PMID:19525930]. Receptor activity is allosterically enhanced by membrane cholesterol, regulated transcriptionally by the IKK-2/IκBα/NF-κB pathway, and antagonized by CXCR3 ligands that bind overlapping extracellular-loop epitopes [PMID:34490352, PMID:11694538, PMID:12884299]."},"prefetch_data":{"uniprot":{"accession":"P51677","full_name":"C-C chemokine receptor type 3","aliases":["Eosinophil eotaxin receptor"],"length_aa":355,"mass_kda":41.0,"function":"G protein-coupled receptor (GPCR) that plays a key role in the immune system by regulating the migration and activation of white blood cells in response to chemokines (PubMed:28994588). Selectively interacts with eosinophil-attracting chemokines such as eotaxin/CCL11, eotaxin-2/CCL24 and eotaxin-3/CCL26 (PubMed:7622448, PubMed:8642344, PubMed:8676064). Ligand binding triggers intracellular signaling that leads to chemotaxis of immune cells. Mechanistically, signals through GNA14 or GNA16 to induce stimulation of phospholipase Cbeta/PLCB2 and subsequently chemotaxis (PubMed:18406577). Alternatively, transduces signal via GNAI1 resulting in elevated intracellular calcium levels and activation of the PI3K/AKT pathway (PubMed:8676064, PubMed:35570218). May also act as a possible functional receptor for NARS1 (PubMed:30171954) (Microbial infection) Alternative coreceptor with CD4 for HIV-1 infection","subcellular_location":"Cell membrane","url":"https://www.uniprot.org/uniprotkb/P51677/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CCR3","classification":"Not Classified","n_dependent_lines":2,"n_total_lines":1208,"dependency_fraction":0.0016556291390728477},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/CCR3","total_profiled":1310},"omim":[{"mim_id":"612007","title":"CELIAC DISEASE, SUSCEPTIBILITY TO, 9; CELIAC9","url":"https://www.omim.org/entry/612007"},{"mim_id":"612006","title":"CELIAC DISEASE, SUSCEPTIBILITY TO, 8; CELIAC8","url":"https://www.omim.org/entry/612006"},{"mim_id":"610247","title":"ESOPHAGITIS, EOSINOPHILIC, 1; EOE1","url":"https://www.omim.org/entry/610247"},{"mim_id":"604836","title":"CHEMOKINE, CC MOTIF, RECEPTOR 4; CCR4","url":"https://www.omim.org/entry/604836"},{"mim_id":"604697","title":"CHEMOKINE, CC MOTIF, LIGAND 26; CCL26","url":"https://www.omim.org/entry/604697"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Plasma membrane","reliability":"Approved"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"intestine","ntpm":2.4},{"tissue":"lymphoid tissue","ntpm":1.5},{"tissue":"skeletal muscle","ntpm":1.6}],"url":"https://www.proteinatlas.org/search/CCR3"},"hgnc":{"alias_symbol":["CC-CKR-3","CKR3","CD193"],"prev_symbol":["CMKBR3"]},"alphafold":{"accession":"P51677","domains":[{"cath_id":"1.20.1070.10","chopping":"26-312","consensus_level":"medium","plddt":92.1038,"start":26,"end":312}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P51677","model_url":"https://alphafold.ebi.ac.uk/files/AF-P51677-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P51677-F1-predicted_aligned_error_v6.png","plddt_mean":83.44},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CCR3","jax_strain_url":"https://www.jax.org/strain/search?query=CCR3"},"sequence":{"accession":"P51677","fasta_url":"https://rest.uniprot.org/uniprotkb/P51677.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P51677/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P51677"}},"corpus_meta":[{"pmid":"8674119","id":"PMC_8674119","title":"The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates.","date":"1996","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/8674119","citation_count":2053,"is_preprint":false},{"pmid":"8674120","id":"PMC_8674120","title":"A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors.","date":"1996","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/8674120","citation_count":1669,"is_preprint":false},{"pmid":"9302298","id":"PMC_9302298","title":"Selective expression of the eotaxin receptor CCR3 by human T helper 2 cells.","date":"1997","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/9302298","citation_count":818,"is_preprint":false},{"pmid":"9005985","id":"PMC_9005985","title":"Chemokine receptor usage by human eosinophils. The importance of CCR3 demonstrated using an antagonistic monoclonal antibody.","date":"1997","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/9005985","citation_count":357,"is_preprint":false},{"pmid":"10975800","id":"PMC_10975800","title":"A novel chemokine ligand for CCR10 and CCR3 expressed by epithelial cells in mucosal tissues.","date":"2000","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/10975800","citation_count":242,"is_preprint":false},{"pmid":"9480044","id":"PMC_9480044","title":"Functional expression of the eotaxin receptor CCR3 in T lymphocytes co-localizing with eosinophils.","date":"1997","source":"Current biology : CB","url":"https://pubmed.ncbi.nlm.nih.gov/9480044","citation_count":218,"is_preprint":false},{"pmid":"11877470","id":"PMC_11877470","title":"CCR3 is essential for skin eosinophilia and airway hyperresponsiveness in a murine model of allergic skin inflammation.","date":"2002","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/11877470","citation_count":213,"is_preprint":false},{"pmid":"11390513","id":"PMC_11390513","title":"Eotaxin (CCL11) induces in vivo angiogenic responses by human CCR3+ endothelial cells.","date":"2001","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/11390513","citation_count":208,"is_preprint":false},{"pmid":"19525930","id":"PMC_19525930","title":"CCR3 is a target for age-related macular degeneration diagnosis and therapy.","date":"2009","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/19525930","citation_count":202,"is_preprint":false},{"pmid":"11110672","id":"PMC_11110672","title":"Functional expression of CCR1, CCR3, CCR4, and CXCR4 chemokine receptors on human platelets.","date":"2000","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/11110672","citation_count":201,"is_preprint":false},{"pmid":"16210640","id":"PMC_16210640","title":"The eotaxin chemokines and CCR3 are fundamental regulators of allergen-induced pulmonary eosinophilia.","date":"2005","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/16210640","citation_count":189,"is_preprint":false},{"pmid":"10900353","id":"PMC_10900353","title":"Expression of the beta-chemokine receptors CCR2, CCR3 and CCR5 in multiple sclerosis central nervous system tissue.","date":"2000","source":"Journal of neuroimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/10900353","citation_count":161,"is_preprint":false},{"pmid":"10417617","id":"PMC_10417617","title":"Enhanced expression of eotaxin and CCR3 in atopic dermatitis.","date":"1999","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/10417617","citation_count":152,"is_preprint":false},{"pmid":"10072545","id":"PMC_10072545","title":"Differential regulation of eosinophil chemokine signaling via CCR3 and non-CCR3 pathways.","date":"1999","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/10072545","citation_count":152,"is_preprint":false},{"pmid":"9289016","id":"PMC_9289016","title":"Distinct but overlapping epitopes for the interaction of a CC-chemokine with CCR1, CCR3 and CCR5.","date":"1997","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9289016","citation_count":149,"is_preprint":false},{"pmid":"9525662","id":"PMC_9525662","title":"Role of the beta-chemokine receptors CCR3 and CCR5 in human immunodeficiency virus type 1 infection of monocytes and microglia.","date":"1998","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/9525662","citation_count":131,"is_preprint":false},{"pmid":"18244953","id":"PMC_18244953","title":"Antisense therapy against CCR3 and the common beta chain attenuates allergen-induced eosinophilic responses.","date":"2008","source":"American journal of respiratory and critical care medicine","url":"https://pubmed.ncbi.nlm.nih.gov/18244953","citation_count":116,"is_preprint":false},{"pmid":"11704586","id":"PMC_11704586","title":"Interleukin-5 induces CD34(+) eosinophil progenitor mobilization and eosinophil CCR3 expression in asthma.","date":"2001","source":"American journal of respiratory and critical care medicine","url":"https://pubmed.ncbi.nlm.nih.gov/11704586","citation_count":109,"is_preprint":false},{"pmid":"10984371","id":"PMC_10984371","title":"Chemokines induce eosinophil degranulation through CCR-3.","date":"2000","source":"The Journal of allergy and clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/10984371","citation_count":108,"is_preprint":false},{"pmid":"12884299","id":"PMC_12884299","title":"CCR3 functional responses are regulated by both CXCR3 and its ligands CXCL9, CXCL10 and CXCL11.","date":"2003","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/12884299","citation_count":106,"is_preprint":false},{"pmid":"11160184","id":"PMC_11160184","title":"Expression of the C-C chemokine receptor CCR3 in human airway epithelial cells.","date":"2001","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/11160184","citation_count":96,"is_preprint":false},{"pmid":"9394815","id":"PMC_9394815","title":"The CC chemokine antagonist Met-RANTES inhibits eosinophil effector functions through the chemokine receptors CCR1 and CCR3.","date":"1997","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/9394815","citation_count":91,"is_preprint":false},{"pmid":"15814620","id":"PMC_15814620","title":"Up-regulation of functional chemokine receptor CCR3 in human renal cell carcinoma.","date":"2005","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/15814620","citation_count":90,"is_preprint":false},{"pmid":"27167205","id":"PMC_27167205","title":"Crosstalk between CCL7 and CCR3 promotes metastasis of colon cancer cells via ERK-JNK signaling pathways.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27167205","citation_count":90,"is_preprint":false},{"pmid":"12496441","id":"PMC_12496441","title":"The CCR3 receptor is involved in eosinophil differentiation and is up-regulated by Th2 cytokines in CD34+ progenitor cells.","date":"2003","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/12496441","citation_count":83,"is_preprint":false},{"pmid":"10380909","id":"PMC_10380909","title":"Depletion of eosinophils in mice through the use of antibodies specific for C-C chemokine receptor 3 (CCR3).","date":"1999","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/10380909","citation_count":83,"is_preprint":false},{"pmid":"24286456","id":"PMC_24286456","title":"Safety and efficacy of an oral CCR3 antagonist in patients with asthma and eosinophilic bronchitis: a randomized, placebo-controlled clinical trial.","date":"2014","source":"Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/24286456","citation_count":78,"is_preprint":false},{"pmid":"20505746","id":"PMC_20505746","title":"Eotaxins and CCR3 interaction regulates the Th2 environment of cutaneous T-cell lymphoma.","date":"2010","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/20505746","citation_count":76,"is_preprint":false},{"pmid":"17148674","id":"PMC_17148674","title":"Eosinophils and CCR3 regulate interleukin-13 transgene-induced pulmonary remodeling.","date":"2006","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/17148674","citation_count":76,"is_preprint":false},{"pmid":"15130922","id":"PMC_15130922","title":"CCL11 (Eotaxin) induces CCR3-dependent smooth muscle cell migration.","date":"2004","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/15130922","citation_count":74,"is_preprint":false},{"pmid":"14561178","id":"PMC_14561178","title":"Eotaxins and CCR3 receptor in inflammatory and allergic skin diseases: therapeutical implications.","date":"2003","source":"Current drug targets. Inflammation and allergy","url":"https://pubmed.ncbi.nlm.nih.gov/14561178","citation_count":74,"is_preprint":false},{"pmid":"35570218","id":"PMC_35570218","title":"Molecular insights into ligand recognition and activation of chemokine receptors CCR2 and CCR3.","date":"2022","source":"Cell discovery","url":"https://pubmed.ncbi.nlm.nih.gov/35570218","citation_count":72,"is_preprint":false},{"pmid":"20608915","id":"PMC_20608915","title":"Robust expression of CCR3 as a single basophil selection marker in flow cytometry.","date":"2011","source":"Allergy","url":"https://pubmed.ncbi.nlm.nih.gov/20608915","citation_count":72,"is_preprint":false},{"pmid":"9616137","id":"PMC_9616137","title":"Interferon-gamma increases expression of chemokine receptors CCR1, CCR3, and CCR5, but not CXCR4 in monocytoid U937 cells.","date":"1998","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/9616137","citation_count":72,"is_preprint":false},{"pmid":"10859315","id":"PMC_10859315","title":"Characterization of binding between the chemokine eotaxin and peptides derived from the chemokine receptor CCR3.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10859315","citation_count":70,"is_preprint":false},{"pmid":"25450766","id":"PMC_25450766","title":"Structural basis of receptor sulfotyrosine recognition by a CC chemokine: the N-terminal region of CCR3 bound to CCL11/eotaxin-1.","date":"2014","source":"Structure (London, England : 1993)","url":"https://pubmed.ncbi.nlm.nih.gov/25450766","citation_count":66,"is_preprint":false},{"pmid":"19223978","id":"PMC_19223978","title":"High-level production, solubilization and purification of synthetic human GPCR chemokine receptors CCR5, CCR3, CXCR4 and CX3CR1.","date":"2009","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/19223978","citation_count":64,"is_preprint":false},{"pmid":"11306952","id":"PMC_11306952","title":"Expression of the chemokine receptor CCR3 on human mast cells.","date":"2001","source":"International archives of allergy and immunology","url":"https://pubmed.ncbi.nlm.nih.gov/11306952","citation_count":59,"is_preprint":false},{"pmid":"29778505","id":"PMC_29778505","title":"Novel peptide nanoparticle-biased antagonist of CCR3 blocks eosinophil recruitment and airway hyperresponsiveness.","date":"2018","source":"The Journal of allergy and clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/29778505","citation_count":59,"is_preprint":false},{"pmid":"11971026","id":"PMC_11971026","title":"IL-16 promotes leukotriene C(4) and IL-4 release from human eosinophils via CD4- and autocrine CCR3-chemokine-mediated signaling.","date":"2002","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/11971026","citation_count":58,"is_preprint":false},{"pmid":"9687538","id":"PMC_9687538","title":"HIV-specific T cell cytotoxicity mediated by RANTES via the chemokine receptor CCR3.","date":"1998","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/9687538","citation_count":55,"is_preprint":false},{"pmid":"24641500","id":"PMC_24641500","title":"Recent progress in the development of antagonists to the chemokine receptors CCR3 and CCR4.","date":"2014","source":"Expert opinion on drug discovery","url":"https://pubmed.ncbi.nlm.nih.gov/24641500","citation_count":54,"is_preprint":false},{"pmid":"11694538","id":"PMC_11694538","title":"The IKK-2/Ikappa Balpha /NF-kappa B pathway plays a key role in the regulation of CCR3 and eotaxin-1 in fibroblasts. A critical link to dermatitis in Ikappa Balpha -deficient mice.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11694538","citation_count":53,"is_preprint":false},{"pmid":"16604092","id":"PMC_16604092","title":"Rosmarinic acid as a downstream inhibitor of IKK-beta in TNF-alpha-induced upregulation of CCL11 and CCR3.","date":"2006","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/16604092","citation_count":51,"is_preprint":false},{"pmid":"9353270","id":"PMC_9353270","title":"Chemokine receptor CCR3 function is highly dependent on local pH and ionic strength.","date":"1997","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9353270","citation_count":49,"is_preprint":false},{"pmid":"14561201","id":"PMC_14561201","title":"Eotaxin receptor (CCR3) antagonism in asthma and allergic disease.","date":"2002","source":"Current drug targets. Inflammation and allergy","url":"https://pubmed.ncbi.nlm.nih.gov/14561201","citation_count":48,"is_preprint":false},{"pmid":"19967721","id":"PMC_19967721","title":"Small molecule antagonists for chemokine CCR3 receptors.","date":"2010","source":"Medicinal research reviews","url":"https://pubmed.ncbi.nlm.nih.gov/19967721","citation_count":48,"is_preprint":false},{"pmid":"27250766","id":"PMC_27250766","title":"Hypoxia induced CCL28 promotes angiogenesis in lung adenocarcinoma by targeting CCR3 on endothelial cells.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/27250766","citation_count":48,"is_preprint":false},{"pmid":"27878757","id":"PMC_27878757","title":"Targeting CCR3 to Reduce Amyloid-β Production, Tau Hyperphosphorylation, and Synaptic Loss in a Mouse Model of Alzheimer's Disease.","date":"2016","source":"Molecular neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/27878757","citation_count":48,"is_preprint":false},{"pmid":"21917937","id":"PMC_21917937","title":"Upregulation of CCR3 by age-related stresses promotes choroidal endothelial cell migration via VEGF-dependent and -independent signaling.","date":"2011","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/21917937","citation_count":45,"is_preprint":false},{"pmid":"23702389","id":"PMC_23702389","title":"The chemokine receptor CCR3 participates in tissue remodeling during atopic skin inflammation.","date":"2013","source":"Journal of dermatological science","url":"https://pubmed.ncbi.nlm.nih.gov/23702389","citation_count":44,"is_preprint":false},{"pmid":"16920975","id":"PMC_16920975","title":"Functional analysis of the chemokine receptor CCR3 on airway epithelial cells.","date":"2006","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/16920975","citation_count":43,"is_preprint":false},{"pmid":"11991282","id":"PMC_11991282","title":"Eotaxin and CCR3 are up-regulated in exacerbations of chronic bronchitis.","date":"2002","source":"Allergy","url":"https://pubmed.ncbi.nlm.nih.gov/11991282","citation_count":42,"is_preprint":false},{"pmid":"21406396","id":"PMC_21406396","title":"CCL11-CCR3 interactions promote survival of anaplastic large cell lymphoma cells via ERK1/2 activation.","date":"2011","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/21406396","citation_count":42,"is_preprint":false},{"pmid":"11354381","id":"PMC_11354381","title":"Discovery of a novel CCR3 selective antagonist.","date":"2001","source":"Bioorganic & medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/11354381","citation_count":42,"is_preprint":false},{"pmid":"21945903","id":"PMC_21945903","title":"CCR3 Blockade Attenuates Eosinophilic Ileitis and Associated Remodeling.","date":"2011","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/21945903","citation_count":40,"is_preprint":false},{"pmid":"10527858","id":"PMC_10527858","title":"Novel association of the src family kinases, hck and c-fgr, with CCR3 receptor stimulation: A possible mechanism for eotaxin-induced human eosinophil chemotaxis.","date":"1999","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/10527858","citation_count":40,"is_preprint":false},{"pmid":"25986216","id":"PMC_25986216","title":"A polymorphism in CCR1/CCR3 is associated with narcolepsy.","date":"2015","source":"Brain, behavior, and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/25986216","citation_count":39,"is_preprint":false},{"pmid":"28387445","id":"PMC_28387445","title":"Stimulation of oral fibroblast chemokine receptors identifies CCR3 and CCR4 as potential wound healing targets.","date":"2017","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/28387445","citation_count":39,"is_preprint":false},{"pmid":"28497923","id":"PMC_28497923","title":"CCR3 Monoclonal Antibody Inhibits Eosinophilic Inflammation and Mucosal Injury in a Mouse Model of Eosinophilic Gastroenteritis.","date":"2017","source":"Allergy, asthma & immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/28497923","citation_count":39,"is_preprint":false},{"pmid":"29547639","id":"PMC_29547639","title":"Interleukin-4 activated macrophages mediate immunity to filarial helminth infection by sustaining CCR3-dependent eosinophilia.","date":"2018","source":"PLoS pathogens","url":"https://pubmed.ncbi.nlm.nih.gov/29547639","citation_count":38,"is_preprint":false},{"pmid":"15948978","id":"PMC_15948978","title":"Tacrolimus decreases the expression of eotaxin, CCR3, RANTES and interleukin-5 in atopic dermatitis.","date":"2005","source":"The British journal of dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/15948978","citation_count":37,"is_preprint":false},{"pmid":"11202173","id":"PMC_11202173","title":"Expression pattern of CXCR3, CXCR4, and CCR3 chemokine receptors in the developing human brain.","date":"2001","source":"Journal of neuropathology and experimental neurology","url":"https://pubmed.ncbi.nlm.nih.gov/11202173","citation_count":37,"is_preprint":false},{"pmid":"17112414","id":"PMC_17112414","title":"CCR3 monoclonal antibody inhibits airway eosinophilic inflammation and mucus overproduction in a mouse model of asthma.","date":"2006","source":"Acta pharmacologica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/17112414","citation_count":36,"is_preprint":false},{"pmid":"23742707","id":"PMC_23742707","title":"PI3K, ERK, p38 MAPK and integrins regulate CCR3-mediated secretion of mouse and human eosinophil-associated RNases.","date":"2013","source":"Allergy","url":"https://pubmed.ncbi.nlm.nih.gov/23742707","citation_count":34,"is_preprint":false},{"pmid":"11920572","id":"PMC_11920572","title":"Alanine scanning mutagenesis of CCR3 reveals that the three intracellular loops are essential for functional receptor expression.","date":"2002","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/11920572","citation_count":34,"is_preprint":false},{"pmid":"10623856","id":"PMC_10623856","title":"Molecular analysis of CCR-3 events in eosinophilic cells.","date":"2000","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/10623856","citation_count":33,"is_preprint":false},{"pmid":"16889234","id":"PMC_16889234","title":"Recent developments in CCR3 antagonists.","date":"2006","source":"Current opinion in drug discovery & development","url":"https://pubmed.ncbi.nlm.nih.gov/16889234","citation_count":33,"is_preprint":false},{"pmid":"17804691","id":"PMC_17804691","title":"Selective suppression of Th2-mediated airway eosinophil infiltration by low-molecular weight CCR3 antagonists.","date":"2007","source":"International immunology","url":"https://pubmed.ncbi.nlm.nih.gov/17804691","citation_count":33,"is_preprint":false},{"pmid":"15802529","id":"PMC_15802529","title":"CXCL9 inhibits eosinophil responses by a CCR3- and Rac2-dependent mechanism.","date":"2005","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/15802529","citation_count":32,"is_preprint":false},{"pmid":"33671956","id":"PMC_33671956","title":"Stromal CCL5 Promotes Breast Cancer Progression by Interacting with CCR3 in Tumor Cells.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33671956","citation_count":32,"is_preprint":false},{"pmid":"20875077","id":"PMC_20875077","title":"Local proliferation and mobilization of CCR3(+)  CD34(+) eosinophil-lineage-committed cells in the lung.","date":"2010","source":"Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/20875077","citation_count":31,"is_preprint":false},{"pmid":"24917456","id":"PMC_24917456","title":"A role for CCL28-CCR3 in T-cell homing to the human upper airway mucosa.","date":"2014","source":"Mucosal immunology","url":"https://pubmed.ncbi.nlm.nih.gov/24917456","citation_count":31,"is_preprint":false},{"pmid":"11683586","id":"PMC_11683586","title":"The presence of chemokine receptor (CCR5, CXCR3, CCR3)-positive cells and chemokine (MCP1, MIP-1alpha, MIP-1beta, IP-10)-positive cells in human periapical granulomas.","date":"2001","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/11683586","citation_count":31,"is_preprint":false},{"pmid":"21660963","id":"PMC_21660963","title":"Pulmonary epithelial CCR3 promotes LPS-induced lung inflammation by mediating release of IL-8.","date":"2011","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/21660963","citation_count":31,"is_preprint":false},{"pmid":"11041848","id":"PMC_11041848","title":"Comparison of the structure of vMIP-II with eotaxin-1, RANTES, and MCP-3 suggests a unique mechanism for CCR3 activation.","date":"2000","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11041848","citation_count":31,"is_preprint":false},{"pmid":"36131165","id":"PMC_36131165","title":"CCL24/CCR3 axis plays a central role in angiotensin II-induced heart failure by stimulating M2 macrophage polarization and fibroblast activation.","date":"2022","source":"Cell biology and toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/36131165","citation_count":30,"is_preprint":false},{"pmid":"23404125","id":"PMC_23404125","title":"Suppression of laser-induced choroidal neovascularization by a CCR3 antagonist.","date":"2013","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/23404125","citation_count":30,"is_preprint":false},{"pmid":"16449815","id":"PMC_16449815","title":"Increased expression of RANTES, CCR3 and CCR5 in the lesional skin of patients with atopic eczema.","date":"2006","source":"International archives of allergy and immunology","url":"https://pubmed.ncbi.nlm.nih.gov/16449815","citation_count":28,"is_preprint":false},{"pmid":"16343433","id":"PMC_16343433","title":"In vitro and in vivo characterization of a novel CCR3 antagonist, YM-344031.","date":"2005","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/16343433","citation_count":27,"is_preprint":false},{"pmid":"19147836","id":"PMC_19147836","title":"Ablation of type I hypersensitivity in experimental allergic conjunctivitis by eotaxin-1/CCR3 blockade.","date":"2009","source":"International immunology","url":"https://pubmed.ncbi.nlm.nih.gov/19147836","citation_count":27,"is_preprint":false},{"pmid":"17983872","id":"PMC_17983872","title":"Genetic effect of CCR3 and IL5RA gene polymorphisms on eosinophilia in asthmatic patients.","date":"2007","source":"The Journal of allergy and clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/17983872","citation_count":26,"is_preprint":false},{"pmid":"26188133","id":"PMC_26188133","title":"Novel CCR3 Antagonists Are Effective Mono- and Combination Inhibitors of Choroidal Neovascular Growth and Vascular Permeability.","date":"2015","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/26188133","citation_count":25,"is_preprint":false},{"pmid":"15219825","id":"PMC_15219825","title":"Activation of epidermal growth factor receptor via CCR3 in bronchial epithelial cells.","date":"2004","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/15219825","citation_count":23,"is_preprint":false},{"pmid":"15379987","id":"PMC_15379987","title":"CD4+ CCR5+ and CD4+ CCR3+ lymphocyte subset and monocyte apoptosis in patients with acute visceral leishmaniasis.","date":"2004","source":"Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/15379987","citation_count":23,"is_preprint":false},{"pmid":"16828880","id":"PMC_16828880","title":"Oligodendrocyte precursor cells express a functional chemokine receptor CCR3: implications for myelination.","date":"2006","source":"Journal of neuroimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/16828880","citation_count":23,"is_preprint":false},{"pmid":"10226056","id":"PMC_10226056","title":"CD4 receptor-dependent entry of human immunodeficiency virus type-1 env-pseudotypes into CCR5-, CCR3-, and CXCR4-expressing human alveolar macrophages is preferentially mediated by the CCR5 coreceptor.","date":"1999","source":"American journal of respiratory cell and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/10226056","citation_count":23,"is_preprint":false},{"pmid":"34490352","id":"PMC_34490352","title":"Cholesterol Is a Dose-Dependent Positive Allosteric Modulator of CCR3 Ligand Affinity and G Protein Coupling.","date":"2021","source":"Frontiers in molecular biosciences","url":"https://pubmed.ncbi.nlm.nih.gov/34490352","citation_count":22,"is_preprint":false},{"pmid":"28458639","id":"PMC_28458639","title":"CCR3 Is Associated with the Death of a Photoreceptor Cell-line Induced by Light Exposure.","date":"2017","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/28458639","citation_count":22,"is_preprint":false},{"pmid":"15507393","id":"PMC_15507393","title":"The Th2 response as monitored by CRTH2 or CCR3 expression is severely decreased during septic shock.","date":"2004","source":"Clinical immunology (Orlando, Fla.)","url":"https://pubmed.ncbi.nlm.nih.gov/15507393","citation_count":22,"is_preprint":false},{"pmid":"37922997","id":"PMC_37922997","title":"IgE directly affects eosinophil migration in chronic rhinosinusitis with nasal polyps through CCR3 and predicts the efficacy of omalizumab.","date":"2023","source":"The Journal of allergy and clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/37922997","citation_count":21,"is_preprint":false},{"pmid":"10708591","id":"PMC_10708591","title":"Cell-type-dependent induction of eotaxin and CCR3 by ionizing radiation.","date":"2000","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/10708591","citation_count":21,"is_preprint":false},{"pmid":"31151084","id":"PMC_31151084","title":"CCL26 and CCR3 are associated with the acute inflammatory response in the CNS in experimental autoimmune encephalomyelitis.","date":"2019","source":"Journal of neuroimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/31151084","citation_count":21,"is_preprint":false},{"pmid":"16461999","id":"PMC_16461999","title":"A specific CCR3 chemokine receptor antagonist inhibits both early and late phase allergic inflammation in the conjunctiva.","date":"2005","source":"Immunologic research","url":"https://pubmed.ncbi.nlm.nih.gov/16461999","citation_count":21,"is_preprint":false},{"pmid":"14561176","id":"PMC_14561176","title":"CCR3 and CXCR3 as drug targets for allergy: principles and potential.","date":"2003","source":"Current drug targets. Inflammation and allergy","url":"https://pubmed.ncbi.nlm.nih.gov/14561176","citation_count":20,"is_preprint":false},{"pmid":"33671469","id":"PMC_33671469","title":"The Chemokine Receptor CCR3 Is Potentially Involved in the Homing of Prostate Cancer Cells to Bone: Implication of Bone-Marrow Adipocytes.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33671469","citation_count":20,"is_preprint":false},{"pmid":"35887133","id":"PMC_35887133","title":"Potent CCR3 Receptor Antagonist, SB328437, Suppresses Colonic Eosinophil Chemotaxis and Inflammation in the Winnie Murine Model of Spontaneous Chronic Colitis.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/35887133","citation_count":20,"is_preprint":false},{"pmid":"11196669","id":"PMC_11196669","title":"New variations of human CC-chemokine receptors CCR3 and CCR4.","date":"1999","source":"Genes and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/11196669","citation_count":20,"is_preprint":false},{"pmid":"18954648","id":"PMC_18954648","title":"CCR3- and CXCR4-mediated interactions regulate migration of CD34+ human bone marrow progenitors to ischemic myocardium and subsequent tissue repair.","date":"2008","source":"The Journal of thoracic and cardiovascular surgery","url":"https://pubmed.ncbi.nlm.nih.gov/18954648","citation_count":20,"is_preprint":false},{"pmid":"33608009","id":"PMC_33608009","title":"Asthma-related inflammation promotes lung metastasis of breast cancer cells through CCL11-CCR3 pathway.","date":"2021","source":"Respiratory research","url":"https://pubmed.ncbi.nlm.nih.gov/33608009","citation_count":20,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":52108,"output_tokens":9730,"usd":0.151137},"stage2":{"model":"claude-opus-4-6","input_tokens":13728,"output_tokens":4292,"usd":0.26391},"total_usd":0.415047,"stage1_batch_id":"msgbatch_011kfMfE81o6CTcyhVUqumuW","stage2_batch_id":"msgbatch_01DTputS6WNkH745x1nVSoBo","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1996,\n      \"finding\": \"CCR3, when co-expressed with CD4 on otherwise non-permissive cells, functions as a co-receptor (fusion cofactor) for a restricted subset of primary HIV-1 isolates; binding of the CCR3 ligand eotaxin blocks this infection, and utilization depends on the V3 region of HIV-1 gp120.\",\n      \"method\": \"Cell-based infection/fusion assay with CCR3 transfectants, co-expression of CD4 and CCR3, chemokine inhibition experiments\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — two independent Cell papers using cell-line reconstitution and functional fusion/infection assays; replicated\",\n      \"pmids\": [\"8674119\", \"8674120\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"CCR3 is selectively expressed on human Th2 cells; eotaxin stimulation through CCR3 induces intracellular calcium increases and chemotaxis of CCR3+ T cells, and these cells produce IL-4 and IL-5.\",\n      \"method\": \"Anti-CCR3 antibody-based cell isolation, intracellular Ca2+ flux assay, chemotaxis assay, cytokine production measurement\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal functional validation with blocking antibody and Ca2+ flux, replicated in multiple labs\",\n      \"pmids\": [\"9302298\", \"9480044\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"CCR3 mediates eosinophil responses (chemotaxis and calcium flux) to multiple CC chemokines including eotaxin, RANTES, MCP-2, MCP-3, and MCP-4; a selective antagonistic monoclonal antibody (7B11) blocks >95% of these responses.\",\n      \"method\": \"Radiolabeled chemokine binding competition assay, calcium flux assay, chemotaxis assay with antagonistic mAb 7B11\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal assays, specific mAb antagonism confirming receptor mediating all responses\",\n      \"pmids\": [\"9005985\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Alanine scanning mutagenesis of RANTES identified distinct but overlapping binding epitopes for CCR3 (F12 in N-loop), CCR1 (R17), and CCR5 (F12, I15, P2); residues P2 and Y3 near the RANTES N-terminus are required for CCR3 signal transduction, defining a two-site model of chemokine-receptor interaction.\",\n      \"method\": \"Alanine scanning mutagenesis of RANTES, receptor binding assays, calcium mobilization assays\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — systematic mutagenesis with binding and functional readouts\",\n      \"pmids\": [\"9289016\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"CCR3 function is highly sensitive to extracellular pH and NaCl concentration; small physiological variations dramatically alter eotaxin binding, CCR3-mediated Ca2+ mobilization, and eosinophil migration, suggesting the tissue microenvironment modulates CCR3 affinity.\",\n      \"method\": \"Radiolabeled ligand binding assay, intracellular Ca2+ mobilization assay, eosinophil migration assay under varied pH and salt conditions\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal in vitro assays in single study\",\n      \"pmids\": [\"9353270\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"CCR3 (but not CCR5) is the essential co-receptor for microglia HIV-1 infection among CCR3/CCR5-expressing cells; antibodies to CCR5 but not CCR3 prevented monocyte infection, establishing differential receptor usage in mononuclear phagocyte subsets.\",\n      \"method\": \"Antibody blockade of CCR3 and CCR5, infection of purified monocyte and microglia populations with macrophage-tropic HIV-1 strains\",\n      \"journal\": \"Journal of virology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct antibody blockade in primary cell infection assays\",\n      \"pmids\": [\"9525662\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"IFN-γ upregulates CCR3 (along with CCR1 and CCR5) surface expression and mRNA in monocytoid U937 cells, resulting in enhanced Ca2+ mobilization, chemotaxis, and increased HIV-1 entry.\",\n      \"method\": \"Flow cytometry, mRNA expression, Ca2+ mobilization, cell migration assays, HIV-1 entry assay in IFN-γ-treated U937 cells\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods in a single study\",\n      \"pmids\": [\"9616137\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"RANTES enhances HIV-1-specific CTL killing via CCR3; the effect is blocked by a CCR3-specific antibody and by pertussis toxin, indicating G protein-coupled CCR3 signaling mediates this cytotoxic enhancement. MCP-3, MCP-4, and eotaxin also enhance lysis through CCR3, while CCR1, CCR2, CCR5, and CXCR4 ligands are inactive.\",\n      \"method\": \"CTL killing assay with specific antibody blockade, pertussis toxin treatment, chemokine panel testing\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional blockade with specific antibody and G-protein inhibitor\",\n      \"pmids\": [\"9687538\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Eotaxin stimulation through CCR3 induces tyrosine phosphorylation of multiple cellular proteins in eosinophils, recruits Src family kinases Hck and c-Fgr to CCR3 after receptor internalization, and causes actin reorganization; herbimycin A (tyrosine kinase inhibitor) blocks both phosphorylation and chemotaxis.\",\n      \"method\": \"Co-immunoprecipitation, immunofluorescence microscopy, tyrosine kinase inhibitor treatment, chemotaxis assay\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — co-IP showing direct association of Hck/c-Fgr with CCR3, functional inhibitor validation\",\n      \"pmids\": [\"10527858\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"CCR3 mediates eosinophil shape change in response to eotaxin, eotaxin-2, MCP-4, and RANTES; MIP-1α induces eosinophil responses through a non-CCR3 pathway (likely CCR1); pre-incubation without extracellular Ca2+ upregulates non-CCR3 signaling pathways.\",\n      \"method\": \"Gated autofluorescence/forward scatter assay for leukocyte shape change, antibody blocking of CCR3\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pathway discrimination using specific antibody blocking in primary cells\",\n      \"pmids\": [\"10072545\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"CCR3 chemokine-induced eosinophil degranulation (release of eosinophil-derived neurotoxin) is mediated exclusively through CCR3; although non-CCR3 ligands (e.g., MCP-1) induce Ca2+ flux, only CCR3 ligands (MCP-3, MCP-4, RANTES, eotaxin) induce degranulation; IL-5 priming enhances CCR3-dependent but not non-CCR3 degranulation.\",\n      \"method\": \"Ca2+ flux assay, RIA for eosinophil-derived neurotoxin, CCR3-specific antibody blocking, IL-5 priming\",\n      \"journal\": \"The Journal of allergy and clinical immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — antibody blockade with multiple chemokines, specific functional readout\",\n      \"pmids\": [\"10984371\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"The N-terminal peptide of CCR3 (residues 1–35 and 8–23) binds eotaxin with low affinity (Kd ~80–136 µM); NMR spectroscopy identified the N-loop/β2-β3 hairpin groove of eotaxin as the binding surface; the central DDYY region of the CCR3 N-terminus is involved in the interaction.\",\n      \"method\": \"Synthetic peptide binding assay, 1H-15N NMR spectroscopy, 15N-filtered TOCSY\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — NMR structural characterization with peptide binding experiments\",\n      \"pmids\": [\"10859315\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"CCR3 signaling in eosinophilic AML14.3D10 cells does not inhibit adenylate cyclase (unlike most GPCRs), uses pertussis toxin-sensitive Ca2+ transients inhibited by PMA but not forskolin, and eotaxin stimulation causes rapid and prolonged receptor internalization without degradation.\",\n      \"method\": \"cAMP assay, Ca2+ flux assay, pertussis toxin and PMA treatment, receptor internalization/degradation assays, CCR3 promoter-luciferase reporter\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple signaling pathway assays in eosinophilic cell line\",\n      \"pmids\": [\"10623856\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"CCL11 (eotaxin) binds with high affinity to CXCR3, which can act as a decoy receptor sequestering CCL11; CXCR3 ligands (CXCL9, CXCL10, CXCL11) inhibit CCR3-mediated eosinophil responses by acting as CCR3 antagonists; CCR3-CCR1 chimeric receptor analysis revealed that CCL11 and CXCL11 share overlapping binding sites in the CCR3 extracellular loops.\",\n      \"method\": \"Binding assays, chemotaxis assay, Ca2+ flux, CCR3-CCR1 chimeric receptor construction and analysis\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — chimeric receptor mapping combined with functional assays\",\n      \"pmids\": [\"12884299\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"CCR3 is expressed on human airway epithelial cells and is functional: eotaxin stimulation induces intracellular Ca2+ flux and tyrosine phosphorylation, blocked by anti-CCR3 mAb (7B11) or pertussis toxin; 125I-eotaxin binding confirmed expected ligand specificity.\",\n      \"method\": \"Northern blot, Western blot, flow cytometry, Ca2+ flux assay, tyrosine phosphorylation assay, 125I-eotaxin binding assay, mAb blockade, pertussis toxin treatment\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods confirming functional receptor expression in a non-leukocyte cell type\",\n      \"pmids\": [\"11160184\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"CCR3 expressed on human mast cells mediates chemotaxis in response to eotaxin and RANTES; pre-incubation with anti-CCR3 antibody abrogates eotaxin-induced mast cell migration, but eotaxin does not induce histamine release from lung mast cells.\",\n      \"method\": \"Immunohistochemistry, flow cytometry, chemotaxis assay with anti-CCR3 antibody blockade, histamine release assay\",\n      \"journal\": \"International archives of allergy and immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — antibody blockade in primary cell chemotaxis and degranulation assays\",\n      \"pmids\": [\"11306952\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"CCL11 (eotaxin) promotes angiogenesis via CCR3 expressed on human microvascular endothelial cells; CCL11-induced endothelial chemotaxis was inhibited by antibodies to CCL11 or CCR3; in vivo angiogenesis (chick CAM and Matrigel assays) was confirmed, and rat aortic sprouting assay showed the response is direct (not eosinophil-mediated).\",\n      \"method\": \"Endothelial chemotaxis assay with antibody blockade, chick chorioallantoic membrane assay, Matrigel plug assay, rat aortic sprouting assay\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple in vivo and in vitro angiogenesis assays with antibody blockade, direct mechanism demonstrated\",\n      \"pmids\": [\"11390513\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"The IKK-2/IκBα/NF-κB pathway regulates CCR3 expression in fibroblasts: transdominant IκBα mutant blocks TNF-α-induced CCR3 expression, and constitutively active IKK-2 drives CCR3 expression without TNF-α; IκBα-deficient mice show elevated CCR3 in skin associated with dermatitis.\",\n      \"method\": \"Stable transfection of IκBα and IKK-2 mutants, luciferase reporter assay, immunohistochemistry in knockout mice, RT-PCR\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — genetic and biochemical pathway dissection with both gain- and loss-of-function mutants in cells and in vivo\",\n      \"pmids\": [\"11694538\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Alanine scanning mutagenesis of CCR3's three intracellular loops revealed all three are required for G protein coupling and chemotactic function; in ICL2, the DRY motif residues D130 and R131 require acidic/basic character for function; Y132 is critical for surface expression and chemotaxis.\",\n      \"method\": \"Site-directed alanine triplet and point mutagenesis, flow cytometry for surface expression, chemotaxis assay\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — systematic mutagenesis (15 triplet + 7 point mutants) with defined structural-functional readouts\",\n      \"pmids\": [\"11920572\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"CCR3 is essential for skin and lung eosinophilia and airway hyperresponsiveness in a murine model of epicutaneous OVA sensitization; CCR3-/- mice lack skin and lung eosinophils and fail to develop AHR despite normal IgE, Th2 cytokines (IL-4/IL-5), and mast cell numbers.\",\n      \"method\": \"CCR3 knockout mouse model, epicutaneous OVA sensitization, histology, BAL cell counts, AHR measurement, cytokine quantification\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — CCR3 KO with rigorous controls and multiple phenotypic readouts\",\n      \"pmids\": [\"11877470\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"IL-16 activates eosinophils via CD4 receptor to release preformed RANTES, which then autocrinally signals through CCR3 to stimulate LTC4 production and preferential IL-4 (not IL-12) release; CCR3 inhibitors (Met-RANTES, anti-CCR3 mAb) and neutralizing anti-eotaxin/anti-RANTES antibodies block these effects.\",\n      \"method\": \"LTC4 and cytokine RIA, antibody blockade (anti-CD4, anti-CCR3, anti-RANTES, anti-eotaxin), pertussis toxin, Met-RANTES antagonism, brefeldin A treatment\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple blocking reagents and mechanistic dissection of autocrine CCR3 signaling pathway\",\n      \"pmids\": [\"11971026\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Eotaxin induces Ca2+ mobilization and chemotaxis in CD34+ cord blood progenitor cells via CCR3, and directly drives eosinophil differentiation from CD34+ progenitors; Th2 cytokines (IL-4, IL-13) upregulate CCR3 on progenitors while IL-12/IFN-γ decrease it; this differentiation is IL-3-, IL-5-, and GM-CSF-independent.\",\n      \"method\": \"In situ RT-PCR, immunostaining, flow cytometry, Ca2+ mobilization assay, in vitro differentiation assay with neutralizing antibodies\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional Ca2+ and differentiation assays with neutralizing antibody controls\",\n      \"pmids\": [\"12496441\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"CCL11 (eotaxin) induces vascular smooth muscle cell (SMC) migration via CCR3; CCR3 mRNA and protein are present in mouse aortic SMCs; migration is inhibited by anti-CCR3 but not anti-CCR2 antibody; CCR3 and CCL11 are upregulated in SMCs after arterial injury.\",\n      \"method\": \"RT-PCR, Western blot, flow cytometry, Boyden chamber chemotaxis, scrape-wound assay with specific antibody blockade, in vivo arterial injury model\",\n      \"journal\": \"Arteriosclerosis, thrombosis, and vascular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple methods including receptor-specific antibody blockade in both in vitro and in vivo contexts\",\n      \"pmids\": [\"15130922\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"CCR3 in bronchial epithelial cells transactivates the epidermal growth factor receptor (EGFR) upon eotaxin stimulation; EGFR tyrosine phosphorylation is dose-dependent; EGFR inhibitor AG1478 blocks CCR3-induced MAP kinase phosphorylation and IL-8 production.\",\n      \"method\": \"Western blot for EGFR phosphorylation, EGFR inhibitor (AG1478) treatment, ELISA for IL-8 in bronchial epithelial cells\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological inhibitor defining EGFR as downstream effector of CCR3\",\n      \"pmids\": [\"15219825\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Eotaxin-2 has a dominant role in airway (luminal) eosinophilia in allergen-induced asthma; combined deletion of eotaxin-1 and eotaxin-2 (DKO) and CCR3 deletion both markedly reduce tissue eosinophilia, abolish organized peribronchial/perivascular eosinophil accumulation, and eotaxin-2 is expressed by macrophages in BAL fluid.\",\n      \"method\": \"Genetic deletion (eotaxin-1 KO, eotaxin-2 KO, eotaxin-1/2 DKO, CCR3 KO), OVA-induced asthma model, BAL and tissue eosinophil counts\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — epistasis analysis with multiple KO combinations showing CCR3 is downstream of eotaxins\",\n      \"pmids\": [\"16210640\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"CXCL9 (Mig) inhibits eosinophil chemoattraction and F-actin formation through a CCR3-dependent mechanism by blocking eotaxin-induced Rac GTPase activation; Rac2-deficient eosinophils show impaired transmigration and actin polymerization, and CXCL9 cannot inhibit responses in CCR3-deficient eosinophils, establishing CCR3 as the mediator of this inhibitory signal.\",\n      \"method\": \"CCR3 and Rac2 gene-targeted eosinophils, F-actin formation assay, Rac GTPase activation assay, transmigration assay\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — genetic deletion of CCR3 and Rac2 combined with biochemical pathway analysis\",\n      \"pmids\": [\"15802529\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Oligodendrocyte precursor cells (OPCs) express functional CCR3; CCL11 stimulation induces intracellular Ca2+ rise and concentration-specific effects: increased proliferation, inhibition of migration, and augmentation of differentiation in primary OPCs.\",\n      \"method\": \"RT-PCR, immunofluorescence, Ca2+ mobilization assay, proliferation, migration, and differentiation assays in primary rat OPCs\",\n      \"journal\": \"Journal of neuroimmunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple functional readouts in primary cells\",\n      \"pmids\": [\"16828880\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"CCR3 on airway epithelial cells mediates wound repair, cell proliferation, and chemotaxis in response to CCL24 (eotaxin-2), with comparable potency to EGF; CCL11 induces upregulation of profibrogenic genes (FGF-1, FGF-5) and CC/CXC chemokines; a selective CCR3 antagonist inhibits these responses.\",\n      \"method\": \"In vitro wound model, fluorometric proliferation and chemotaxis assays, pathway-specific gene arrays, CCR3 antagonist blockade, immunostaining of bronchial biopsies\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal functional assays with pharmacological inhibitor validation\",\n      \"pmids\": [\"16920975\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"CCR3 is specifically expressed on choroidal neovascular endothelial cells in AMD patients; genetic or pharmacological targeting of CCR3 or its eotaxin ligands inhibits injury-induced CNV in mice; CNV suppression by CCR3 blockade is due to direct inhibition of endothelial cell proliferation, is uncoupled from inflammation, and occurs in mice lacking eosinophils or mast cells.\",\n      \"method\": \"Immunohistochemistry, CCR3 genetic knockout/pharmacological blockade, laser-induced CNV mouse model, in vitro endothelial cell proliferation assay in mice lacking eosinophils/mast cells, quantum dot in vivo imaging\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple genetic and pharmacological approaches with rigorous controls separating CCR3 function from inflammation\",\n      \"pmids\": [\"19525930\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Activated CCR3 promotes choroidal endothelial cell (CEC) migration and Rac1 activation; ligand-activated CCR3 causes transphosphorylation and co-immunoprecipitation of VEGFR2 with CCR3, demonstrating cross-talk between CCR3 and VEGF signaling pathways; CCR3 inhibitor prevents VEGF-induced CEC migration and Rac1 activation.\",\n      \"method\": \"CCL11-stimulated CEC migration assay, Rac1 activity assay, phospho-Akt and phospho-VEGFR2 Western blot, co-immunoprecipitation of CCR3 and VEGFR2, CCR3 inhibitor treatment\",\n      \"journal\": \"Investigative ophthalmology & visual science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — co-IP demonstrating physical interaction plus multiple downstream signaling readouts\",\n      \"pmids\": [\"21917937\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"CCL11 promotes survival of anaplastic large cell lymphoma cells via CCR3-mediated ERK1/2 phosphorylation, inducing anti-apoptotic proteins Bcl-xL and survivin; ERK phosphorylation inhibition completely blocks CCL11-mediated cell survival; autocrine CCL11-CCR3 signaling drives tumor growth in vivo.\",\n      \"method\": \"Cell viability assay, Western blot for ERK1/2 phosphorylation and Bcl-xL/survivin, ERK inhibitor treatment, in vivo tumor growth in CCR3+ cell lines\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ERK pathway inhibitor dissection with in vivo validation\",\n      \"pmids\": [\"21406396\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"CCR3 on human dermal fibroblasts mediates intracellular Ca2+ mobilization, enhanced fibroblast migration, and wound repair capacity in response to CCL26 (eotaxin-3); CCL26 is specifically upregulated in atopic (vs. psoriatic) skin by IL-4 and IL-13, implicating CCR3-mediated CCL26-fibroblast signaling in atopic skin tissue remodeling.\",\n      \"method\": \"Flow cytometry, immunofluorescence, Ca2+ mobilization assay, cell proliferation, migration, and repair capacity assays in dermal fibroblasts\",\n      \"journal\": \"Journal of dermatological science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple functional assays in primary cells with cytokine regulation\",\n      \"pmids\": [\"23702389\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"CCR3-mediated secretion of eosinophil-associated RNases (EARs) requires activation of PI3K, ERK, and p38 MAPK, and is Gαi-dependent; β1 and β2 integrins are essential for EAR secretion, and spreading is obligatory for secretion in both mouse and human eosinophils.\",\n      \"method\": \"RNase activity assay, specific signaling inhibitors for PI3K/ERK/p38 MAPK, integrin blocking antibodies, pertussis toxin, adhesion microscopy in primary mouse and human eosinophils\",\n      \"journal\": \"Allergy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pathway dissection with multiple specific inhibitors in primary cells\",\n      \"pmids\": [\"23742707\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Sulfotyrosine residues in the N-terminal region (residues 8–23) of CCR3 dramatically enhance binding to CCL11/eotaxin-1; crystal structure of CCL11 bound to sulfo-CCR3(8–23) peptide reveals sulfotyrosine residues form hydrophobic, salt bridge, and cation-π interactions with conserved CC chemokine residues; intact CCR3 is sulfated in cells and sulfation enhances receptor activity.\",\n      \"method\": \"X-ray crystallography (NMR structure of peptide-chemokine complex), sulfopeptide binding assays, receptor activity assays, mass spectrometry for sulfation\",\n      \"journal\": \"Structure\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure with functional validation of sulfotyrosine-mediated receptor-ligand recognition\",\n      \"pmids\": [\"25450766\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"CCL11 (CCR3 ligand) activates CDK5 and GSK-3β via CCR3, leading to tau hyperphosphorylation, Aβ production, and dendritic spine loss in hippocampal neurons; CCR3 deletion in APP/PS1 mice significantly reduces CDK5/GSK-3β phosphorylation, tau hyperphosphorylation, Aβ deposition, and synaptic loss; all CCL11 effects are blocked by CCR3 antagonist GW766994.\",\n      \"method\": \"Primary hippocampal neuronal culture, Western blot for CDK5/GSK-3β/tau phosphorylation, Aβ ELISA, dendritic spine analysis, CCR3 KO in AD transgenic mice, CCR3 antagonist treatment\",\n      \"journal\": \"Molecular neurobiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — genetic (KO) and pharmacological (specific antagonist) approaches with multiple downstream mechanistic readouts\",\n      \"pmids\": [\"27878757\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"CCL7-CCR3 interaction in colon cancer cells promotes cellular proliferation, invasion, and migration via ERK and JNK signaling pathways; CCL7-overexpressing cells form faster-growing tumors and develop liver/lung metastases in orthotopic mouse models.\",\n      \"method\": \"CCL7-overexpressing HCT116/HT29 cell lines, in vitro proliferation/invasion/migration assays, ERK/JNK Western blots, ectopic and orthotopic mouse tumor models\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vitro signaling plus in vivo tumor models\",\n      \"pmids\": [\"27167205\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"A biased CCR3 peptide nanoparticle antagonist (R321) inhibits only the early phase of ERK1/2 activation (not the late β-arrestin-associated phase), promotes CCR3 internalization and degradation, and effectively blocks eosinophil recruitment and airway hyperresponsiveness in a mouse asthma model.\",\n      \"method\": \"Dynamic light scattering, NMR peptide binding, flow cytometry, confocal microscopy, Western blot for ERK1/2 phases, in vivo triple-allergen mouse asthma model\",\n      \"journal\": \"The Journal of allergy and clinical immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — biased signaling mechanism demonstrated with multiple methods in vitro and in vivo\",\n      \"pmids\": [\"29778505\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Cholesterol acts as a dose-dependent positive allosteric modulator of CCR3: increasing cholesterol concentration enhances CCR3 affinity for CCL11 in both SMALPs and proteoliposomes, and this heightened receptor activation directly increases GTPase activity of the bound Gαi3 subunit.\",\n      \"method\": \"In vitro CCR3 reconstitution in SMALPs and proteoliposomes, ligand binding assay, GTPase activity assay with purified E. coli-expressed CCR3\",\n      \"journal\": \"Frontiers in molecular biosciences\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted in vitro with purified receptor, direct biochemical measurement of allosteric modulation of both binding and G protein activity\",\n      \"pmids\": [\"34490352\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Cryo-EM structure of CCR3 in the apo state and functional analysis show that interactions around intracellular loop 2 (ICL2) are conserved and play a more critical role in G-protein activation than ICL3 interactions; extensive hydrophobic and polar interactions between CCR3 and Gα contribute to constitutive receptor activity.\",\n      \"method\": \"Cryo-electron microscopy structure determination, complementary functional experiments (G protein coupling assays)\",\n      \"journal\": \"Cell discovery\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — cryo-EM structure with functional validation\",\n      \"pmids\": [\"35570218\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"The CCL24/CCR3 axis promotes cardiac fibroblast activation and M2 macrophage polarization; CCR3 is expressed on cardiac macrophages and fibroblasts; CCL24 promotes primary cardiac fibroblast activation through its G protein-coupled receptor function; CCL24 antibody treatment prevents Ang II-induced cardiac hypertrophy and fibrosis.\",\n      \"method\": \"Immunofluorescence co-localization, RNA-seq, CyTOF single-cell analysis, in vitro fibroblast activation assay, in vivo Ang II heart failure model with CCL24 antibody\",\n      \"journal\": \"Cell biology and toxicology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods linking CCR3 GPCR function to fibroblast activation\",\n      \"pmids\": [\"36131165\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CCR3 is a Gαi-coupled, seven-transmembrane CC chemokine receptor that is expressed on eosinophils, basophils, mast cells, Th2 lymphocytes, airway epithelial cells, endothelial cells, smooth muscle cells, and certain neurons/oligodendrocytes; upon binding to eotaxins (CCL11/24/26), RANTES, MCP-3, MCP-4, or CCL7/CCL28, it triggers pertussis toxin-sensitive Ca2+ flux, Src-family kinase (Hck/c-Fgr) recruitment, PI3K-ERK-p38 MAPK activation, Rac2-dependent actin reorganization, receptor internalization, and—in specialized contexts—EGFR transactivation and VEGFR2 cross-talk, thereby driving eosinophil chemotaxis, degranulation, and EAR secretion, Th2 cell recruitment, endothelial angiogenesis, smooth muscle cell migration, fibroblast wound repair, and choroidal neovascularization; its activity is regulated by sulfotyrosine-mediated high-affinity ligand binding at the receptor N-terminus, cholesterol allosteric modulation of Gαi coupling, NF-κB (IKK-2/IκBα)-dependent transcription, and antagonism by CXCR3 ligands acting as CCR3 receptor antagonists.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"CCR3 is a Gαi-coupled seven-transmembrane CC chemokine receptor that orchestrates eosinophil recruitment, degranulation, and effector function in allergic inflammation, while also mediating angiogenesis, tissue remodeling, and neurodegeneration in non-hematopoietic contexts. The receptor binds eotaxins (CCL11/CCL24/CCL26), RANTES, MCP-3, MCP-4, and CCL7 via an N-terminal sulfotyrosine-dependent recognition site, triggering pertussis toxin-sensitive Ca²⁺ flux, Src-family kinase (Hck/c-Fgr) recruitment, PI3K–ERK–p38 MAPK activation, and Rac2-dependent actin reorganization that collectively drive chemotaxis, shape change, and eosinophil-associated RNase secretion [PMID:9005985, PMID:10527858, PMID:23742707, PMID:25450766]. Beyond leukocytes, CCR3 functions on airway epithelial cells, endothelial cells, smooth muscle cells, fibroblasts, and neurons, where it transactivates EGFR, cross-talks with VEGFR2, and activates CDK5/GSK-3β to promote wound repair, choroidal neovascularization, and tau hyperphosphorylation respectively [PMID:15219825, PMID:21917937, PMID:27878757, PMID:19525930]. Receptor activity is allosterically enhanced by membrane cholesterol, regulated transcriptionally by the IKK-2/IκBα/NF-κB pathway, and antagonized by CXCR3 ligands that bind overlapping extracellular-loop epitopes [PMID:34490352, PMID:11694538, PMID:12884299].\",\n  \"teleology\": [\n    {\n      \"year\": 1996,\n      \"claim\": \"Identification of CCR3 as a functional chemokine receptor that also serves as an HIV-1 co-receptor established it as a seven-transmembrane signaling molecule with dual roles in chemokine biology and viral entry.\",\n      \"evidence\": \"Cell-based infection/fusion assays with CCR3 transfectants co-expressing CD4, ligand competition\",\n      \"pmids\": [\"8674119\", \"8674120\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream signaling events upon HIV-1 gp120 engagement of CCR3 undefined\", \"Whether CCR3 serves as HIV-1 co-receptor in vivo undetermined\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Demonstration that CCR3 is the dominant receptor mediating eosinophil and Th2 cell chemotaxis to multiple CC chemokines (eotaxin, RANTES, MCP-2/3/4) established its central role in type 2 immune cell trafficking.\",\n      \"evidence\": \"Antagonistic mAb 7B11, Ca²⁺ flux, radiolabeled binding competition, Th2 isolation and cytokine profiling\",\n      \"pmids\": [\"9005985\", \"9302298\", \"9480044\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Intracellular signaling cascade downstream of CCR3 not yet mapped\", \"Relative contribution of each ligand in vivo unknown\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Alanine scanning of RANTES and characterization of CCR3 sensitivity to pH/NaCl defined a two-site chemokine–receptor interaction model and revealed that microenvironmental conditions tune CCR3 ligand affinity.\",\n      \"evidence\": \"Systematic RANTES mutagenesis with binding/Ca²⁺ assays; ligand binding under varied ionic/pH conditions\",\n      \"pmids\": [\"9289016\", \"9353270\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis for pH sensitivity not determined\", \"In vivo relevance of microenvironmental modulation unproven\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Discovery that eotaxin-activated CCR3 recruits Src-family kinases Hck and c-Fgr and drives actin reorganization linked receptor engagement to a defined tyrosine kinase signaling axis required for eosinophil chemotaxis.\",\n      \"evidence\": \"Co-immunoprecipitation of Hck/c-Fgr with CCR3 post-internalization, herbimycin A inhibition, immunofluorescence\",\n      \"pmids\": [\"10527858\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No reciprocal pull-down or direct binding assay for Hck/c-Fgr–CCR3 interaction\", \"Kinase substrates downstream of Hck/c-Fgr not identified\", \"Role of receptor internalization in kinase recruitment unclear\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Functional dissection revealed that CCR3 exclusively mediates eosinophil degranulation (EDN release) even though non-CCR3 pathways can trigger Ca²⁺ flux, and NMR mapping identified the CCR3 N-terminal DDYY region and eotaxin N-loop groove as the initial binding interface.\",\n      \"evidence\": \"CCR3-specific antibody blocking of degranulation vs. Ca²⁺; ¹H-¹⁵N NMR of eotaxin–CCR3 peptide complex\",\n      \"pmids\": [\"10984371\", \"10859315\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full-length receptor–ligand complex structure not solved\", \"Structural basis for coupling between binding and degranulation signaling not established\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Extending CCR3 function beyond leukocytes, studies showed it mediates angiogenesis in endothelial cells, signals in airway epithelium, directs mast cell chemotaxis, and is transcriptionally regulated by the IKK-2/IκBα/NF-κB pathway.\",\n      \"evidence\": \"Chick CAM/Matrigel/aortic ring angiogenesis assays, epithelial Ca²⁺ flux and tyrosine phosphorylation, mast cell migration with anti-CCR3, gain/loss-of-function IKK-2/IκBα mutants and IκBα-KO mice\",\n      \"pmids\": [\"11390513\", \"11160184\", \"11306952\", \"11694538\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"NF-κB binding sites on CCR3 promoter not mapped\", \"Relative importance of CCR3 vs. VEGFR signaling in angiogenesis unclear\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"CCR3 knockout mice lack eosinophilic inflammation and airway hyperresponsiveness in allergic models, and systematic intracellular-loop mutagenesis defined the DRY motif and all three ICLs as essential for G protein coupling, establishing CCR3 as non-redundant for allergic eosinophilia in vivo.\",\n      \"evidence\": \"CCR3-KO epicutaneous OVA model; alanine-scanning mutagenesis of 15 ICL triplets with chemotaxis readout\",\n      \"pmids\": [\"11877470\", \"11920572\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Other compensatory receptors in chronic settings not evaluated\", \"Exact Gα subunit preference at ICL interfaces not biochemically defined\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Genetic epistasis showed eotaxin-1/eotaxin-2 double knockouts phenocopy CCR3 deletion for airway eosinophilia, and CXCL9 was found to inhibit CCR3-mediated Rac2 activation directly through the receptor, establishing a natural antagonist mechanism.\",\n      \"evidence\": \"Multiple KO combinations in OVA asthma model; Rac2-KO and CCR3-KO eosinophil F-actin and transmigration assays\",\n      \"pmids\": [\"16210640\", \"15802529\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis for CXCR3-ligand antagonism at CCR3 not resolved\", \"Role of Rac1 vs. Rac2 in different CCR3-expressing cell types not distinguished\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"CCR3 was identified as specifically expressed on choroidal neovascular endothelium in AMD patients, and its blockade inhibited CNV independently of eosinophils/mast cells, establishing a direct pro-angiogenic function.\",\n      \"evidence\": \"Immunohistochemistry of human AMD tissue, CCR3-KO and pharmacological blockade in laser-induced CNV, endothelial proliferation in eosinophil/mast-cell-deficient mice\",\n      \"pmids\": [\"19525930\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Which eotaxin drives CNV in human AMD not determined\", \"Clinical efficacy of CCR3 blockade in AMD not validated\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"CCR3 transphosphorylates and physically associates with VEGFR2 in choroidal endothelial cells, and drives ALCL survival through ERK–Bcl-xL/survivin, revealing receptor cross-talk and pro-survival signaling as additional mechanistic outputs.\",\n      \"evidence\": \"Co-IP of CCR3–VEGFR2, phospho-VEGFR2/Akt/Rac1 Western blots; ERK inhibitor blockade of ALCL cell survival and in vivo tumor growth\",\n      \"pmids\": [\"21917937\", \"21406396\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether CCR3–VEGFR2 complex forms in other vascular beds unknown\", \"Direct kinase responsible for VEGFR2 transphosphorylation not identified\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"CCR3-mediated EAR secretion was mapped to a Gαi→PI3K→ERK/p38 MAPK cascade requiring integrin-dependent spreading, and CCL26–CCR3 was shown to drive dermal fibroblast wound repair, expanding the receptor's downstream signaling map and tissue-remodeling roles.\",\n      \"evidence\": \"Specific signaling inhibitors and integrin-blocking antibodies in primary eosinophils; Ca²⁺/migration/wound-repair assays in dermal fibroblasts\",\n      \"pmids\": [\"23742707\", \"23702389\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"PI3K isoform specificity not determined\", \"Whether integrin requirement reflects co-signaling or physical constraint not resolved\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Crystal structure of the sulfo-CCR3 N-terminal peptide bound to CCL11 revealed that sulfotyrosine residues form specific salt-bridge, hydrophobic, and cation-π contacts with conserved chemokine residues, explaining high-affinity ligand recognition.\",\n      \"evidence\": \"X-ray crystallography of sulfo-CCR3(8–23)–CCL11 complex, mass spectrometry confirming sulfation, receptor activity assays\",\n      \"pmids\": [\"25450766\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full-length CCR3–CCL11 complex structure not solved\", \"Contribution of individual sulfotyrosines to in vivo signaling not determined\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"CCR3 activation by CCL11 in neurons triggers CDK5/GSK-3β-mediated tau hyperphosphorylation and Aβ production; CCR3 deletion in APP/PS1 mice reduces Alzheimer-related pathology, linking CCR3 to neurodegeneration.\",\n      \"evidence\": \"CCR3-KO crossed with APP/PS1 transgenic mice, CCR3 antagonist GW766994, Western blots for tau/CDK5/GSK-3β phosphorylation, Aβ ELISA, dendritic spine analysis\",\n      \"pmids\": [\"27878757\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Source of CCL11 in the AD brain not identified\", \"Whether CCR3 blockade is therapeutic after disease onset unknown\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"A biased CCR3 peptide nanoparticle antagonist (R321) selectively inhibits early G protein-dependent ERK activation while sparing β-arrestin-mediated signaling, promoting receptor degradation and blocking eosinophil recruitment in vivo, demonstrating pharmacologically exploitable signaling bias.\",\n      \"evidence\": \"NMR peptide binding, ERK phase dissection by Western blot, confocal internalization/degradation, triple-allergen mouse asthma model\",\n      \"pmids\": [\"29778505\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"β-arrestin pathway contributions to CCR3 biology in vivo not resolved\", \"Single study; biased agonism not independently confirmed\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Reconstitution of purified CCR3 in defined lipid environments demonstrated that cholesterol is a dose-dependent positive allosteric modulator, directly enhancing both CCL11 binding affinity and Gαi3 GTPase activity.\",\n      \"evidence\": \"Purified E. coli-expressed CCR3 in SMALPs and proteoliposomes with titrated cholesterol, GTPase activity assay\",\n      \"pmids\": [\"34490352\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cholesterol binding site on CCR3 not structurally identified\", \"Physiological range of membrane cholesterol variation in eosinophils not characterized\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Cryo-EM structure of apo CCR3 revealed that ICL2 interactions with Gα are more critical than ICL3 for G protein activation and provided structural basis for constitutive receptor activity, completing the structural picture of CCR3–G protein coupling.\",\n      \"evidence\": \"Cryo-EM structure determination with complementary G protein coupling functional assays\",\n      \"pmids\": [\"35570218\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Ligand-bound active-state cryo-EM structure not yet solved\", \"Structural basis for biased signaling (G protein vs. β-arrestin) not resolved\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"A complete structural understanding of CCR3 activation—including a full-length CCR3–chemokine–Gi ternary complex structure, the molecular basis for β-arrestin-biased signaling, and the cholesterol binding site—remains to be determined.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No ternary complex structure of full-length CCR3–ligand–Gi\", \"Molecular basis of β-arrestin-biased vs. G protein-biased signaling unknown\", \"In vivo therapeutic efficacy of CCR3-targeted agents in AMD and neurodegeneration not established\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [1, 2, 9, 12, 14, 38]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [25, 36, 37]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [1, 2, 14, 15, 16, 22, 28, 38]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:0162582\", \"supporting_discovery_ids\": [1, 2, 8, 12, 18, 23, 25, 29, 30, 32, 34, 37, 38]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [1, 2, 7, 10, 19, 20, 24, 25, 32, 36]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [8, 12, 18, 23, 25, 29, 30, 32, 34, 37, 38]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"CCL11\",\n      \"CCL24\",\n      \"CCL26\",\n      \"CCL5\",\n      \"VEGFR2\",\n      \"HCK\",\n      \"FGR\",\n      \"RAC2\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}